var title_f19_57_20368="Carmustine lung fibrosis CT";
var content_f19_57_20368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carmustine-induced pulmonary fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT scan in a patient with carmustine (BCNU)-induced pulmonary fibrosis. There are coarse linear strands, many of which are subpleural in distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronan O'Driscoll, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20368=[""].join("\n");
var outline_f19_57_20368=null;
var title_f19_57_20369="Patient information: Heart block in children (The Basics)";
var content_f19_57_20369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/49/6931\">",
"         Patient information: Pacemakers (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heart block in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heart-block-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H4618255\">",
"      <span class=\"h1\">",
"       What is heart block in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Heart block is a condition that affects the heartbeat. Heart block in children can be mild or serious. Mild types of heart block can cause a child&rsquo;s heart to beat more slowly than normal or to skip beats. More serious types can cause a child&rsquo;s heart to stop beating. Without emergency treatment, serious heart block can be fatal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4618270\">",
"      <span class=\"h1\">",
"       What causes heart block in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Heart block happens when the electrical signals that tell the heart to beat either get slowed slow down or stopped. This can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A problem with the heart that happened before the child was born. These heart problems are called &ldquo;congenital heart defects.&rdquo; Congenital means a condition a person is born with.",
"       </li>",
"       <li>",
"        Surgery for another congenital heart defect",
"       </li>",
"       <li>",
"        Other heart problems, diseases, or injuries",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4618287\">",
"      <span class=\"h1\">",
"       What are the symptoms of heart block?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the type of heart block your child has. There are 3 types of heart block:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        First degree &ndash; This is the mildest type of heart block. Often, children with this type have no symptoms.",
"       </li>",
"       <li>",
"        Second degree &ndash; This type is more serious than first degree. Symptoms include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Fainting",
"       </li>",
"       <li>",
"        Feeling dizzy",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Third degree &ndash; This is the most serious type of heart block. It can cause the same symptoms as second degree, but they will be more severe. In some cases, third degree heart block can be life-threatening.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4618302\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your child will have one or both of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram &ndash; This test, also called an &ldquo;ECG&rdquo; or &ldquo;EKG,&rdquo; measures the electrical activity in the heart.",
"       </li>",
"       <li>",
"        A Holter monitor &ndash; This is a small, portable machine the child wears that records all the heart&rsquo;s electrical activity over 1 or 2 days.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4618317\">",
"      <span class=\"h1\">",
"       How is heart block treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the type of heart block your child has and his or her symptoms. Often, children who have first degree heart block do not need treatment. But children who have third degree heart block and some who have second or first degree heart block need a pacemaker. A pacemaker is a device that goes under the skin near the heart. It sends electrical signals to the heart that help it beat normally.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4618332\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"       Patient information: Pacemakers (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/57/20369?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83745 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20369=[""].join("\n");
var outline_f19_57_20369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4618255\">",
"      What is heart block in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4618270\">",
"      What causes heart block in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4618287\">",
"      What are the symptoms of heart block?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4618302\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4618317\">",
"      How is heart block treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4618332\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20370="Manometry in achalasia";
var content_f19_57_20370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manometric features of achalasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are three characteristic manometric features of achalasia: elevated resting lower esophageal sphincter (LES) pressure (above 45 mmHg); incomplete LES relaxation after a swallow (S); aperistalsis in the smooth muscle portion of the body of the esophagus. Swallows may elicit no esophageal contraction or may be followed by simultaneous contractions. The esophagus may also contract spontaneously in a simultaneous fashion. In some cases, the simultaneous esophageal contractions have amplitudes &gt;60 mmHg, a condition known as \"vigorous\" achalasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted, courtesy of the Clinical Teaching Project of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20370=[""].join("\n");
var outline_f19_57_20370=null;
var title_f19_57_20371="Patient information: Cystic fibrosis (The Basics)";
var content_f19_57_20371=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16906\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/27/20914\">",
"         Organs most affected by cystic fibrosis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40850\">",
"         Patient information: Bronchiectasis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/43/22195\">",
"         Patient information: Coughing up blood (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/9/19603\">",
"         Patient information: Lung transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/49/26386\">",
"         Patient information: Poor weight gain in babies and children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/7/18547\">",
"         Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44083\">",
"         Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/18/8486\">",
"         Patient information: Poor weight gain in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cystic fibrosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cystic-fibrosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11002751\">",
"      <span class=\"h1\">",
"       What is cystic fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cystic fibrosis is a disease that some children are born with. It causes thick mucus and other fluids to build up and clog different parts of the body, including the lungs, pancreas, liver, and intestine (",
"      <a class=\"graphic graphic_figure graphicRef74980 \" href=\"UTD.htm?20/27/20914\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The thick mucus in the lungs causes people with cystic fibrosis to get frequent lung infections. Over time, these infections damage the lungs. The thick fluids in the pancreas and liver keep the intestine from absorbing certain nutrients from food. This affects a child&rsquo;s growth and causes abnormal bowel movements.",
"     </p>",
"     <p>",
"      Cystic fibrosis is caused by an abnormal gene. To get the disease, people need to get the abnormal gene from both their mother and father. If people get the abnormal gene from only 1 parent, they will not have cystic fibrosis. But they will have a chance of passing on the abnormal gene to their children.",
"     </p>",
"     <p>",
"      Cystic fibrosis is a life-long condition. As of now, doctors can&rsquo;t cure the disease, but they can use different treatments to help with symptoms.",
"     </p>",
"     <p>",
"      People with cystic fibrosis don&rsquo;t live as long as people without the disease. But better treatments are helping people with cystic fibrosis live longer. To help manage your child&rsquo;s disease for as long as possible, it&rsquo;s important to work closely with his or her doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11002766\">",
"      <span class=\"h1\">",
"       What are the symptoms of cystic fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can have different symptoms at different times. Most people start having symptoms as a baby or young child. A few people start having symptoms as teens or adults. A person&rsquo;s symptoms usually get worse over time.",
"     </p>",
"     <p>",
"      Common symptoms of cystic fibrosis include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not growing or gaining weight normally",
"       </li>",
"       <li>",
"        A long-lasting cough &ndash; The cough usually brings up mucus (it sounds &ldquo;wet&rdquo;). Some people cough up blood.",
"       </li>",
"       <li>",
"        Trouble breathing or breathing that sounds like whistling (wheezing)",
"       </li>",
"       <li>",
"        Frequent infections of the lungs or sinuses &ndash; The sinuses are hollow areas in the bones of the face.",
"       </li>",
"       <li>",
"        Skin that tastes salty (for example, you might taste salt when you kiss your child)",
"       </li>",
"       <li>",
"        Belly pain, diarrhea, or constipation (trouble having bowel movements)",
"       </li>",
"       <li>",
"        Bowel movements that are oily, bad-smelling, and float in the toilet bowl",
"       </li>",
"       <li>",
"        Infertility &ndash; Infertility is when a woman has trouble getting pregnant, and a man has trouble getting a woman pregnant.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11002781\">",
"      <span class=\"h1\">",
"       Is there a test for cystic fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If a person has symptoms of cystic fibrosis, or if he or she has a family member with the disease, his or her doctor can do a test to check for the disease. The different tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A &ldquo;sweat test&rdquo; &ndash; During this test, the doctor makes a person sweat and then measures the amount of salt in the sweat.",
"       </li>",
"       <li>",
"        Blood tests to check for the abnormal gene",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Cystic fibrosis testing can also happen at other times. Some pregnant women choose to test their unborn baby for the disease. Plus, every baby in the U.S. is tested for the disease at birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11002798\">",
"      <span class=\"h1\">",
"       How is cystic fibrosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with cystic fibrosis can have different treatments to help with symptoms and prevent further problems.",
"     </p>",
"     <p>",
"      Treatments to help the lungs can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotic medicines to help prevent or treat infections",
"       </li>",
"       <li>",
"        Medicines to help open up the airways in the lungs",
"       </li>",
"       <li>",
"        Medicines to help thin out the mucus in the lungs",
"       </li>",
"       <li>",
"        Chest physiotherapy &ndash; This involves breaking up and loosening the mucus in the lungs. There is more than 1 way to do this, and your child&rsquo;s doctor or nurse can show you the different ways. One way involves thumping your child&rsquo;s chest and back to loosen the mucus. Other ways involve using special devices. These include a vibrating vest or devices children breathe into.",
"       </li>",
"       <li>",
"        A lung transplant &ndash; This is surgery in which a doctor replaces a person&rsquo;s diseased lungs with healthy lungs. A lung transplant is done only if people have severe disease and meet certain conditions.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatments to help the digestive system can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Taking medicines (called &ldquo;enzymes&rdquo;) to help break down the food in the intestines &ndash; For most children, this involves taking enzymes at every meal and snack.",
"       </li>",
"       <li>",
"        Following a special diet",
"       </li>",
"       <li>",
"        Taking vitamins",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11002813\">",
"      <span class=\"h1\">",
"       How can I help my child stay as healthy as possible?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help your child stay as healthy as possible, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Help him or her gain enough weight. Ask the doctor or nurse which foods are best to feed your child.",
"       </li>",
"       <li>",
"        Not let anyone smoke in the home.",
"       </li>",
"       <li>",
"        Have him or her get regular exercise.",
"       </li>",
"       <li>",
"        Follow all your doctor&rsquo;s instructions about treatments and visits.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can help keep your child from getting an infection by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Having your child get the vaccines his or her doctor recommends. Vaccines are treatments to prevent infections.",
"       </li>",
"       <li>",
"        Washing your hands and your child&rsquo;s hands often.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11002828\">",
"      <span class=\"h1\">",
"       How can I learn more about cystic fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To learn more about cystic fibrosis, talk with your child&rsquo;s doctor or nurse. The Cystic Fibrosis Foundation also has a lot of information. Their website is",
"      <a class=\"external\" href=\"file://www.cff.org/\">",
"       www.cff.org",
"      </a>",
"      . Their toll-free phone number in the U.S. is 1-800-344-4823.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11002843\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"       Patient information: Coughing up blood (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/49/26386?source=see_link\">",
"       Patient information: Poor weight gain in babies and children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=see_link\">",
"       Patient information: Bronchiectasis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=see_link\">",
"       Patient information: Lung transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/18/8486?source=see_link\">",
"       Patient information: Poor weight gain in infants and children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/57/20371?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16906 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20371=[""].join("\n");
var outline_f19_57_20371=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002751\">",
"      What is cystic fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002766\">",
"      What are the symptoms of cystic fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002781\">",
"      Is there a test for cystic fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002798\">",
"      How is cystic fibrosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002813\">",
"      How can I help my child stay as healthy as possible?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002828\">",
"      How can I learn more about cystic fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002843\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/27/20914\">",
"      Organs most affected by cystic fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=related_link\">",
"      Patient information: Bronchiectasis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=related_link\">",
"      Patient information: Lung transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/49/26386?source=related_link\">",
"      Patient information: Poor weight gain in babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/18/8486?source=related_link\">",
"      Patient information: Poor weight gain in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20372="Pirbuterol: Drug information";
var content_f19_57_20372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pirbuterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/48/43780?source=see_link\">",
"    see \"Pirbuterol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/1/26?source=see_link\">",
"    see \"Pirbuterol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F10147393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Advisory: Phase Out of MDI Inhalers Containing CFCs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2010",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA), in accordance with the Montreal Protocol on Substances that Deplete the Ozone Layer, has issued a phase out of seven metered-dose inhalers (MDI) containing ozone-depleting chlorofluorocarbons (CFCs). The CFC-propelled Maxair&reg; Autohaler&reg; (pirbuterol) will not be manufactured, sold, or dispensed in the U.S. after December 31, 2013, and patients should be transitioned to another therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information may be found at",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxair&reg; Autohaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bronchospasm:",
"     </b>",
"     Inhalation: 2 inhalations every 4-6 hours for prevention; 2 inhalations at an interval of at least 1-3 minutes, followed by a third inhalation in treatment of bronchospasm, not to exceed 12 inhalations/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F210599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/1/26?source=see_link\">",
"      see \"Pirbuterol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxair&reg; Autohaler&reg;: 200 mcg/actuation (14 g) [contains chlorofluorocarbon; 400 actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F210567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation: Shake inhaler well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of reversible bronchospasm including asthma",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum glucose increased, serum potassium decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Trembling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste changes, vomiting, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arrhythmias, chest pain, hypertension, hypokalemia, insomnia, paradoxical bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pirbuterol, albuterol, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Optimize anti-inflammatory treatment before initiating maintenance treatment with albuterol. Do not use as a component of chronic therapy without an anti-inflammatory agent. Only the mildest forms of asthma (Step 1 and/or exercise-induced) would not require concurrent use based upon asthma guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or heart failure); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. All patients should utilize a spacer device when using a metered-dose inhaler.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Adverse events have been observed in some animal reproduction studies with oral administration. Beta-agonists may interfere with uterine contractility if administered during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F210588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F210572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Maxair Autohaler Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg/INH (14 g): $204.29",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F210561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate; FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Broncocor (IT);",
"     </li>",
"     <li>",
"      Broncocor[inhal.] (IT);",
"     </li>",
"     <li>",
"      Exirel (AT, GB);",
"     </li>",
"     <li>",
"      Exirel[inhal.] (AT, GB);",
"     </li>",
"     <li>",
"      Maxair (CH);",
"     </li>",
"     <li>",
"      Maxair Autohaler (FR);",
"     </li>",
"     <li>",
"      Spirolair (BE, LU);",
"     </li>",
"     <li>",
"      Zeisin Autohaler (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pirbuterol is a beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonist with a similar structure to albuterol, specifically a pyridine ring has been substituted for the benzene ring in albuterol. The increased beta",
"     <sub>",
"      2",
"     </sub>",
"     selectivity of pirbuterol results from the substitution of a tertiary butyl group on the nitrogen of the side chain, which additionally imparts resistance of pirbuterol to degradation by monoamine oxidase and provides a lengthened duration of action in comparison to the less selective previous beta-agonist agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F210569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Therapeutic: Oral: 2-3 hours with peak serum concentration of 6.2-9.8 mcg/L; Inhalation: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9780 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20372=[""].join("\n");
var outline_f19_57_20372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10147393\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210581\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210608\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210584\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210599\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210585\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210563\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210548\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210567\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210566\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210606\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210570\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210552\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299886\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210557\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210559\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079703\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210588\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210572\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210561\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038769\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210551\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210569\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/48/43780?source=related_link\">",
"      Pirbuterol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/1/26?source=related_link\">",
"      Pirbuterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20373="Sports-related groin pain or 'sports hernia'";
var content_f19_57_20373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sports-related groin pain or 'sports hernia'",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20373/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20373/contributors\">",
"     David C Brooks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20373/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20373/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20373/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20373/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20373/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/57/20373/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"sports hernia\" is used to describe a condition characterized by groin pain, often in an athlete, in which there is no demonstrable hernia. The term is a misnomer because there is typically no true hernia or defect in the groin or abdominal wall.",
"   </p>",
"   <p>",
"    A variety of other terms have been used interchangeably to describe this condition including \"sportsman's hernia\", \"hockey groin\", and \"athletic pubalgia\". Over the last decade this condition has become more commonly described as several well-known professional athletes have undergone surgical treatment of this condition.",
"   </p>",
"   <p>",
"    Sports hernia was described initially in Europe, but has become a common diagnosis in high intensity athletes in the United States as well. It is not confined to professional athletes, however, and has been described in youths, college and recreational athletes.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of sports hernia will be discussed here. True groin hernias are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=see_link\">",
"     \"Overview of treatment for inguinal and femoral hernias\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic definition of sports hernia is any condition causing persistent unilateral pain in the groin without demonstrable hernia. Sports hernia, therefore, is a clinical diagnosis. Inguinal hernia is clinically absent, but in virtually all reported series a small number of occult hernias are identified at the time of surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sports hernias result from chronic, repetitive trauma or stress to the musculotendinous portions of the groin. They typically develop in an insidious fashion without sudden or dramatic pain. Symptoms typically come from overuse of the lower abdominal musculature and the muscles of the upper thigh.",
"   </p>",
"   <p>",
"    Sports hernias are more common in men than in women, and are more common with sports such as hockey, soccer, rugby, and football, in which the athlete bends or leans forward. However, virtually all sports can produce sports hernia because leaning or bending forward into the typical \"athletic stance\" is a common pose in any athletic endeavor. Additionally, high speed twisting, turning and torquing the groin likely contribute to the development of the condition.",
"   </p>",
"   <p>",
"    Risk factors for the development of sports hernia were investigated in high-performance hockey players [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/1\">",
"     1",
"    </a>",
"    ]. Subjects were evaluated for degree of off-season training, peak isometric adductor torque, total hip abduction flexibility, prior injury, degree of NHL experience and measurement of skate blade hollowness. Variables predictive of groin injury were confined to those with prior injury, those who did not condition aggressively during the off-season, and veteran (older) players. Similar findings have been reported in other series examining a greater variety of athletes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable pathologic abnormalities have been described, all related to repetitive strain in the inguinal region. Early reports suggested that the primary culprit was a tear of the external oblique aponeurosis with subsequent injury to the ilioinguinal nerve as it coursed through this area (",
"    <a class=\"graphic graphic_figure graphicRef63080 \" href=\"UTD.htm?14/61/15313\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/2\">",
"     2",
"    </a>",
"    ]. Other conditions thought to be responsible for the condition include osteitis pubis (inflammation of the pubic tubercle) and musculotendinous strain to the adductor muscles.",
"   </p>",
"   <p>",
"    A study from the United Kingdom performed exploratory inguinal surgery on 35 patients with groin pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/3\">",
"     3",
"    </a>",
"    ]. Nearly two thirds of patients had a tear in the external oblique aponeurosis. Other patients were found to have torn conjoined tendons, small direct hernias, weak posterior wall, and lipomas of the spermatic cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147095144\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sports hernia is made in a patient who participates in high intensity sports and has typical symptoms with no evidence of hernia or other common injuries (eg, adductor muscle strain) on physical examination. Groin pain is the predominant symptom and is often exacerbated by sudden increases in intra-abdominal pressure, as can accompany coughing or sneezing. Straining at defecation can also cause mild discomfort.",
"   </p>",
"   <p>",
"    Examination of the groin fails to detect a typical bulge or the \"silky\" sensation of an impulse with coughing or straining. Frequently, the symptoms can be reproduced by simple maneuvers such as performing sit-ups or crunches [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/4\">",
"     4",
"    </a>",
"    ]. Further examination is performed with the patient in a supine position with their knees bent and heels together (so-called frog position). If the patient has pain or discomfort with forced adduction against the examiner&rsquo;s resistance this is suggestive of a sports hernia. Additional tests include putting the athlete into positions of stress from their particular sport and applying resistance to see if this reproduces symptoms. An example would be to have a soccer player assume the position of kicking across their body and resist the internal rotation and adduction of the lower leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147095137\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, most surgeons order an imaging study prior to surgical treatment; the choice of MRI or ultrasound depends upon local expertise and availability. In patients with sports hernia, magnetic resonance imaging (MRI) may reveal abnormalities of the pectineus and rectus abdominus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], and a large field view that includes the pubic symphysis can provide important information about the extent and location of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound, particularly dynamic ultrasound, probably offers the best method for diagnosing abnormalities in the inguinal canal. However, ultrasound is operator-dependent and the diagnosis of sports hernia requires a radiologist or clinician with expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/10\">",
"     10",
"    </a>",
"    ]. Ultrasound examination of the floor of the inguinal canal by an experienced ultrasonographer may demonstrate occult hernias and occasionally demonstrates conjoint &ldquo;tendonitis,&rdquo; attenuation of the conjoint tendon, and indirect evidence of tendonitis of the adductor longus.",
"   </p>",
"   <p>",
"    If osteitis pubis is considered in the differential diagnosis, technetium-99m bone scan may be obtained and generally demonstrates increased uptake in the region of the pubis and loss of the &ldquo;clear stripe&rdquo; that separates the bony margins of the symphysis. Such findings are not present with sports hernia. Anteroposterior (AP) plain radiographs of the pelvis are generally not helpful but if obtained they may demonstrate boney abnormalities consistent with osteitis pubis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147095130\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for sports hernia includes the large differential of groin pain. Included in this differential are osteitis pubis, distal abdominal rectus strain or avulsion, adductor tenoperiostitis, and rupture of the adductor longus. A simple adductor muscle strain (ie, &ldquo;groin pull&rdquo;), or a true hernia that was missed initially on physical examination, should also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various treatments have been recommended for sports hernia, but surgery is generally the mainstay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial conservative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rest is a simple but important part of initial care. Patients who insist on continuing athletic endeavors will take considerably longer to heal any injury to the groin. In addition, following acute injury the application of ice packs 3 to 4 times per day for approximately 10 minutes is beneficial, as may be treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or another non-steroidal anti-inflammatory medication. Once acute symptoms subside, gentle rehabilitation exercises performed under the guidance of a knowledgeable physical therapist, athletic trainer, or other clinician may be helpful in some cases.",
"   </p>",
"   <p>",
"    However, often these simple interventions do not provide long-term relief. Typically, after brief periods of rest, the",
"    <span class=\"nowrap\">",
"     athlete/patient",
"    </span>",
"    experiences a recurrence of the symptoms once they renew their activity. Moreover, many high-performance professional athletes find it impossible to take the prolonged rest necessary to heal the groin completely.",
"   </p>",
"   <p>",
"    Patients who do not improve with a trial of conservative treatment should be referred to a surgeon. Physical therapy is an alternative for patients who can afford to resume activities, including sports activities, at a slow pace. However, for high performance athletes, the delay caused by a lengthy program of physical therapy is often unacceptable and prompt surgical evaluation is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical exploration and repair is the mainstay of treatment for sports hernia, although few randomized trials have been performed to confirm the effectiveness of this approach. In a randomized trial of 60 patients, including many high level athletes, with chronic groin pain diagnosed as sports hernia (minimum three months of symptoms), 27 of the 30 patients treated with laparoscopic surgery and mesh placement returned to full sport activity within three months of the procedure, compared to 8 of 30 managed with physical therapy and other nonsurgical interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/11\">",
"     11",
"    </a>",
"    ]. At one year follow-up, 29 of 30 surgical patients had returned to full activity, while seven of the patients treated conservatively during the study period subsequently opted for surgery and also returned to full sport activity; the remainder of the nonsurgical patients continued to experience disabling symptoms.",
"   </p>",
"   <p>",
"    Before proceeding to surgery, it is important to rule out adductor muscle injury as the cause of symptoms. Adductor injuries are best treated with physical therapy, although in rare cases (eg, complete tendon rupture) surgery may be needed.",
"   </p>",
"   <p>",
"    Surgical exploration can be performed either laparoscopically or open using an anterior approach. The former restricts the surgeon to simply placing prosthetic mesh in the preperitoneal space and dividing nerve fibers (specifically the genito-femoral nerve as it passes through the internal ring) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The standard preperitoneal laparoscopic approach involves using polypropylene or polyester mesh, though biologic inserts have also been employed with good results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/14\">",
"     14",
"    </a>",
"    ]. A potential complication of mesh hernia repair, the development of infection, is discussed separately. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=see_link\">",
"     \"Overview of treatment for inguinal and femoral hernias\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Alternatively, an open anterior approach allows for greater precision in identifying the abnormality and in tailoring the corrective surgery to the specific pathophysiologic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In most cases, anterior approaches will demonstrate injury to the aponeurosis of the external oblique with an associated injury to the ilioinguinal nerve. Neurectomy or neural ablation is often employed to minimize long-term persistent dysesthesia. Standard anterior hernia approaches are also used with good effect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggest that long-term improvement is seen in up to 90 percent of surgically treated patients, although relapses can occur in a small number [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Outcomes in reported series do not appear to depend on the approach used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. However, only one prospective study involving 16 subjects has objectively evaluated strength outcomes following surgery and rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/18\">",
"     18",
"    </a>",
"    ]. Its authors concluded that pain may reduce lower limb strength as a result of disuse atrophy or pain-related muscle inhibition, and that relief of pain following surgery and rehabilitation can improve performance.",
"   </p>",
"   <p>",
"    Complications from sports hernia repair appear to be uncommon. In an observational study of 5460 procedures, hematomas developed in 0.3 percent of patients, superficial surgical site infections occurred in 0.4 percent, and 0.3 percent of patients developed dysesthesias of the ilioinguinal, genitofemoral, and anterior or lateral femoral cutaneous nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20373/abstract/16\">",
"     16",
"    </a>",
"    ]. Dysesthesias resolved in half of the affected patients within 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/56/4994?source=see_link\">",
"       \"Patient information: Groin strain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painful, unilateral groin pain is a common complaint of high-performance as well as recreational athletes. In the absence of a true hernia or other common injuries (eg, adductor muscle strain), this condition may be referred to as \"sports hernia.\" (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of sports hernia is multifactorial but often involves injury and disruption of the aponeurosis of the external oblique muscle with concomitant injury to the ilioinguinal nerve. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sports hernia occurs most often in men who participate in high intensity sports such as hockey, soccer (football), rugby, and American football. Groin pain is the predominant symptom and is often exacerbated by sudden increases in intra-abdominal pressure, as can accompany coughing or sneezing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When symptoms do not resolve with rest and appropriate conservative therapy, we suggest surgical repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Both laparoscopic and anterior approaches have been used with equivalent outcomes. &nbsp;(See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      According to observational studies, long-term outcomes are successful in up to 90 percent of surgical patients, with appropriate rehabilitation, stretching, and conditioning. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/1\">",
"      Emery CA, Meeuwisse WH. Risk factors for groin injuries in hockey. Med Sci Sports Exerc 2001; 33:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/2\">",
"      Irshad K, Feldman LS, Lavoie C, et al. Operative management of \"hockey groin syndrome\": 12 years of experience in National Hockey League players. Surgery 2001; 130:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/3\">",
"      Kumar A, Doran J, Batt ME, et al. Results of inguinal canal repair in athletes with sports hernia. J R Coll Surg Edinb 2002; 47:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/4\">",
"      LeBlanc KE, LeBlanc KA. Groin pain in athletes. Hernia 2003; 7:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/5\">",
"      Albers SL, Spritzer CE, Garrett WE Jr, Meyers WC. MR findings in athletes with pubalgia. Skeletal Radiol 2001; 30:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/6\">",
"      Overdeck KH, Palmer WE. Imaging of hip and groin injuries in athletes. Semin Musculoskelet Radiol 2004; 8:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/7\">",
"      Nelson EN, Kassarjian A, Palmer WE. MR imaging of sports-related groin pain. Magn Reson Imaging Clin N Am 2005; 13:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/8\">",
"      Omar IM, Zoga AC, Kavanagh EC, et al. Athletic pubalgia and \"sports hernia\": optimal MR imaging technique and findings. Radiographics 2008; 28:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/9\">",
"      Robinson P, Bhat V, English B. Imaging in the assessment and management of athletic pubalgia. Semin Musculoskelet Radiol 2011; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/10\">",
"      Koulouris G. Imaging review of groin pain in elite athletes: an anatomic approach to imaging findings. AJR Am J Roentgenol 2008; 191:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/11\">",
"      Paajanen H, Brinck T, Hermunen H, Airo I. Laparoscopic surgery for chronic groin pain in athletes is more effective than nonoperative treatment: a randomized clinical trial with magnetic resonance imaging of 60 patients with sportsman's hernia (athletic pubalgia). Surgery 2011; 150:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/12\">",
"      Srinivasan A, Schuricht A. Long-term follow-up of laparoscopic preperitoneal hernia repair in professional athletes. J Laparoendosc Adv Surg Tech A 2002; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/13\">",
"      Paajanen H, Syv&auml;huoko I, Airo I. Totally extraperitoneal endoscopic (TEP) treatment of sportsman's hernia. Surg Laparosc Endosc Percutan Tech 2004; 14:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/14\">",
"      Edelman DS, Selesnick H. \"Sports\" hernia: treatment with biologic mesh (Surgisis): a preliminary study. Surg Endosc 2006; 20:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/15\">",
"      Steele P, Annear P, Grove JR. Surgery for posterior inguinal wall deficiency in athletes. J Sci Med Sport 2004; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/16\">",
"      Meyers WC, McKechnie A, Philippon MJ, et al. Experience with \"sports hernia\" spanning two decades. Ann Surg 2008; 248:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/17\">",
"      Ahumada LA, Ashruf S, Espinosa-de-los-Monteros A, et al. Athletic pubalgia: definition and surgical treatment. Ann Plast Surg 2005; 55:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20373/abstract/18\">",
"      Hemingway AE, Herrington L, Blower AL. Changes in muscle strength and pain in response to surgical repair of posterior abdominal wall disruption followed by rehabilitation. Br J Sports Med 2003; 37:54.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3689 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20373=[""].join("\n");
var outline_f19_57_20373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147095144\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147095137\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H147095130\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial conservative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/3689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/3689|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15313\" title=\"figure 1\">",
"      Inguinal region",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=related_link\">",
"      Overview of treatment for inguinal and femoral hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/56/4994?source=related_link\">",
"      Patient information: Groin strain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20374="Intrapartum management of the low birthweight vertex fetus";
var content_f19_57_20374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrapartum management of the low birthweight vertex fetus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Jane Cleary-Goldman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Julian N Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20374/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/57/20374/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of the preterm and low birthweight fetus is often necessitated by maternal and fetal indications, including nonreassuring fetal status, intractable preterm labor, chorioamnionitis, abruption, placental insufficiency, hypertensive disorders, and other maternal factors (see individual topic reviews on these subjects). The prognosis for survival of these neonates continues to improve and can be attributed, in part, to widespread use of antenatal corticosteroids in women at risk for preterm birth, liberal use of cesarean delivery for fetal indications, improvements in neonatal resuscitation, use of surfactant therapy, and delivery at facilities with personnel experienced in neonatal intensive care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low birthweight neonates are subgrouped according to the degree of smallness at the first weight determination after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birthweight (LBW): less than 2500 g",
"     </li>",
"     <li>",
"      Very low birthweight (VLBW): less than 1500 g",
"     </li>",
"     <li>",
"      Extremely low birthweight (ELBW): less than 1000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAPARTUM ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398691850\">",
"    <span class=\"h2\">",
"     Hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm births should occur in hospitals with nurseries able to provide an appropriate level of care. A meta-analysis of adequate and high-quality studies of the association between nursery level at birth and neonatal mortality found that VLBW infants born in hospitals with level I or II nurseries had higher mortality than those born in hospitals with level III nurseries (36 versus 21 percent; OR 1.60, 95% CI 1.33-1.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/6\">",
"     6",
"    </a>",
"    ]. When analyzed by gestational age, infants &le;32 weeks of gestation born in hospitals with level I or II nurseries had higher mortality than those with level III nurseries (12 versus 7 percent; OR 1.42, 95% CI 1.06-1.88).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous intrapartum fetal heart rate monitoring of the LBW fetus is important. Reassuring fetal heart rate patterns in the LBW fetus correlate well with normal umbilical arterial pH, while nonreassuring tracings are associated with neonatal acidosis at delivery (",
"    <a class=\"graphic graphic_table graphicRef69589 \" href=\"UTD.htm?0/23/379\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pediatric referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;These infants should be evaluated in the delivery room by personnel with appropriate training in the care of LBW neonates. Ideally, neonatal providers should have an opportunity to talk to and assess the gravida on the Labor and Delivery Unit well before the birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Maternal analgesia/anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal maternal",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    for labor and delivery of a LBW fetus is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The choice should be guided by maternal needs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .) An advantage of epidural anesthesia is that it may reduce trauma to the fetal head by relaxing the pelvic floor and creating less soft tissue resistance. However, epidural anesthesia will occasionally cause hypotension leading to nonreassuring fetal heart rate patterns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .) Parenteral opiates may cause neonatal depression; nevertheless, administration of parenteral opiates to the mother should not be withheld as these agents can be reversed, if required, during neonatal resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is used across gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/11\">",
"     11",
"    </a>",
"    ]. We are not aware of any studies suggesting that fetal risks of oxytocin use are higher preterm; however, the uterus is more resistant to the effects of oxytocin at earlier gestational ages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MODE OF DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cesarean versus vaginal",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in term pregnancies, the goal of intrapartum management of the LBW fetus is the avoidance of perinatal acidosis and birth trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/12\">",
"     12",
"    </a>",
"    ]. The optimal mode of delivery for women at high risk of delivering a small baby is controversial. The rationale for proposals for routine cesarean delivery of these fetuses is based on the hypothesis that avoidance of labor and vaginal delivery might improve survival by reducing hypoxic stress, intracranial trauma, and intraventricular hemorrhage (IVH). However, for the vertex fetus, most retrospective studies of outcome with cesarean versus vaginal delivery have not demonstrated improvements in outcome with cesarean birth when the primary indication was LBW [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/2,12-24\">",
"     2,12-24",
"    </a>",
"    ]. A consistent limitation of these studies is marked differences in baseline characteristics between the cesarean and vaginal delivery groups.",
"   </p>",
"   <p>",
"    There is inconsistent evidence of neonatal benefits from cesarean birth of VLBW infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. Two studies that analyzed US national birth certificate data (1999-2000 and 2000-2003) reported a survival advantage among VLBW vertex neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/25\">",
"     25",
"    </a>",
"    ] and neonates of 22 to 25 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/28\">",
"     28",
"    </a>",
"    ] delivered by cesarean; however, the cesarean deliveries were not analyzed according to whether they were performed as a routine because of prematurity or for standard obstetrical indications (eg, nonreassuring fetal heart rate pattern, failure to progress). Further analysis of the first series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/25\">",
"     25",
"    </a>",
"    ] showed that the survival advantage was limited to small for gestational age infants under 31 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/26\">",
"     26",
"    </a>",
"    ], but this limitation was not observed in the second series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/28\">",
"     28",
"    </a>",
"    ]. Others have also reported a possible benefit of cesarean delivery limited to small for gestational age VLBW infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/29\">",
"     29",
"    </a>",
"    ]. A Cochrane review of four randomized trials (n = 116 women) comparing cesarean versus vaginal delivery for preterm singletons did not find statistically significant differences in any perinatal outcome between groups, but the number of pregnancies was too small to allow any conclusions about the optimal route of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/31\">",
"     31",
"    </a>",
"    ]. More data are needed before a recommendation for cesarean can be considered.",
"   </p>",
"   <p>",
"    An additional important consideration is that cesarean delivery of LBW fetuses, especially those that are VLBW or ELBW, is more likely to require a vertical or classical hysterotomy incision. This places the mother at increased risk of postoperative complications and complications in future pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link&amp;anchor=H3#H3\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no high quality evidence that mode of delivery or avoidance of fetal head compression are important factors in preventing development of IVH in fetuses without a bleeding diathesis. The following examples are representative of observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Route of delivery (cesarean versus vaginal) and method of vaginal delivery (spontaneous versus low forceps) were evaluated in a study of 280 laboring patients who delivered neonates weighing less than 2000 grams from vertex presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/14\">",
"       14",
"      </a>",
"      ]. Neonatal ultrasound was performed on all of the neonates to look for evidence of early",
"      <span class=\"nowrap\">",
"       periventricular/intraventricular",
"      </span>",
"      hemorrhage. There was no evidence of correlation between early periventricular or intraventricular hemorrhage and delivery route or method.",
"     </li>",
"     <li>",
"      A population based study including 1599 infants with birthweight less than 1000 g and 3039 infants with birthweight 1000 to 1500 g found the odds of severe intraventricular hemorrhage were not influenced by mode of delivery in singleton vertex infants, after controlling for gestational age (cesarean versus vaginal delivery: OR 0.98, 95% CI 0.77-1.24) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/32\">",
"       32",
"      </a>",
"      ]. There was also no difference between groups in neonatal mortality or the combined outcome of severe intraventricular hemorrhage and neonatal mortality.",
"     </li>",
"     <li>",
"      A study of 101 infants weighing 500 to 1500 g showed that factors believed to affect head compression, such as parity, labor, cesarean delivery, preterm premature rupture of membranes, and use of episiotomy and forceps did not correlate with the frequency of intraventricular hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/12\">",
"       12",
"      </a>",
"      ]. However, neonatal status (eg, one minute Apgar score less than 7, birthweight less than 1250 g, respiratory distress syndrome) was associated with a significantly increased risk of intraventricular hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"       \"Management and complications of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are minimal data from randomized studies of elective cesarean delivery versus expectant management with planned vaginal delivery of LBW fetuses. A Cochrane review found six trials with a total of only 122 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/13\">",
"     13",
"    </a>",
"    ]. Most of these fetuses were in noncephalic presentation; vaginal delivery of the breech fetus poses additional risks, which are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link\">",
"     \"Delivery of the fetus in breech presentation\"",
"    </a>",
"    .) There were too few subjects to allow reasonably valid estimates of the risks and benefits of either mode of delivery. However, the authors did observe that one in six babies did not deliver by the method to which they were allocated, in part due to precipitous deliveries and to nonreassuring fetal heart rate patterns.",
"   </p>",
"   <p>",
"    Others have hypothesized that labor has a deleterious effect on the preterm fetal brain and have suggested that cesarean delivery may only reduce neonatal morbidity if it is performed before the fetus is exposed to labor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/35\">",
"     35",
"    </a>",
"    ]. However, elective cesarean delivery performed in an attempt to avoid exposing the fetus to the potentially deleterious effects of labor might lead to unnecessarily early delivery since expectant management of many pregnancy complications can lead to significant prolongation of pregnancy with further fetal growth and maturation. Furthermore, preterm labor itself is the most common cause or contributing factor to delivery of LBW neonates and thus cannot be avoided in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Episiotomy and forceps",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the use of episiotomy and forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/36\">",
"     36",
"    </a>",
"    ] was recommended to decrease perineal resistance, thus minimizing trauma to the head of the LBW fetus. However, subsequent studies have not demonstrated improved outcomes with prophylactic episiotomy or instrumental delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. As an example, 1065 liveborn neonates at a single tertiary center were evaluated over a three-year time period to determine if delivery by low forceps decreased neonatal morbidity and mortality when compared to nonoperative vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20374/abstract/40\">",
"     40",
"    </a>",
"    ]. All infants weighed between 1000 and 2500 grams, were singleton, and delivered in the vertex presentation. Neonatal morbidity and mortality were similar for the 394 infants delivered by forceps and the 671 infants who delivered spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous intrapartum fetal monitoring and pediatric presence at delivery are recommended because of the high risk status of these",
"      <span class=\"nowrap\">",
"       fetuses/neonates.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fetal monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choice of maternal analgesia can be guided primarily by maternal needs. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Maternal analgesia/anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A policy of elective cesarean delivery is associated with known risks to the mother, but the benefits to the low birthweight (LBW) neonate in cephalic presentation are uncertain. Standard obstetrical care aimed at avoiding a depressed neonate seems to be a better strategy for preventing intraventricular hemorrhage (IVH) than routine cesarean delivery in vertex LBW fetuses. Delivery of the breech fetus is a separate issue. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link\">",
"       \"Delivery of the fetus in breech presentation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Episiotomy and forceps are recommended for the usual obstetrical indications. Vacuum delivery is contraindicated in fetuses delivering at less than 34 weeks of gestation due to the risk of fetal intraventricular hemorrhage. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Episiotomy and forceps'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=see_link\">",
"       \"Procedure for vacuum assisted operative vaginal delivery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American College of Obstetricians and Gynecologists. Perinatal care at the threshold of viability. ACOG Practice Bulletin #38. American College of Obstetricians and Gynecologists. Washington DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/2\">",
"      Worthington D, Davis LE, Grausz JP, Sobocinski K. Factors influencing survival and morbidity with very low birth weight delivery. Obstet Gynecol 1983; 62:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/3\">",
"      National Institutes of Health Consensus Development Conference Statement. Effect of corticosteroids for fetal maturation on perinatal outcomes. February 28 to March 2, 1994. Am J Obstet Gynecol 1995; 173: 246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/4\">",
"      Phibbs CS, Bronstein JM, Buxton E, Phibbs RH. The effects of patient volume and level of care at the hospital of birth on neonatal mortality. JAMA 1996; 276:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/5\">",
"      Yeast JD, Poskin M, Stockbauer JW, Shaffer S. Changing patterns in regionalization of perinatal care and the impact on neonatal mortality. Am J Obstet Gynecol 1998; 178:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/6\">",
"      Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2000 period linked birth/infant death data set. Natl Vital Stat Rep 2002; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/7\">",
"      Bowes WA Jr, Gabre SG, Bowes C. Fetal heart rate monitoring in premature infants weighing 1,500 grams or less. Am J Obstet Gynecol 1980; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/8\">",
"      Zanini B, Paul RH, Huey JR. Intrapartum fetal heart rate: correlation with scalp pH in the preterm fetus. Am J Obstet Gynecol 1980; 136:43.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbe, SG, Niebyl, JR, Simpson, JL. Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingston Inc, New York 2003.",
"    </li>",
"    <li>",
"     Creasy, RK, Resnik, R. Maternal Fetal Medicine, 5th ed, W.B. Saunders Company, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/11\">",
"      Alexander JM, Bloom SL, McIntire DD, Leveno KJ. Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Obstet Gynecol 1999; 93:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/12\">",
"      Welch RA, Bottoms SF. Reconsideration of head compression and intraventricular hemorrhage in the vertex very-low-birth-weight fetus. Obstet Gynecol 1986; 68:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/13\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/14\">",
"      Tejani N, Verma U, Hameed C, Chayen B. Method and route of delivery in the low birth weight vertex presentation correlated with early periventricular/intraventricular hemorrhage. Obstet Gynecol 1987; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/15\">",
"      Hack M, Fanaroff AA. Outcomes of extremely-low-birth-weight infants between 1982 and 1988. N Engl J Med 1989; 321:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/16\">",
"      Barrett JM, Boehm FH, Vaughn WK. The effect of type of delivery on neonatal outcome in singleton infants of birth weight of 1,000 g or less. JAMA 1983; 250:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/17\">",
"      Malloy MH, Rhoads GG, Schramm W, Land G. Increasing cesarean section rates in very low-birth weight infants. Effect on outcome. JAMA 1989; 262:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/18\">",
"      Malloy MH, Onstad L, Wright E. The effect of cesarean delivery on birth outcome in very low birth weight infants. National Institute of Child Health and Human Development Neonatal Research Network. Obstet Gynecol 1991; 77:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/19\">",
"      Kitchen W, Ford GW, Doyle LW, et al. Cesarean section or vaginal delivery at 24 to 28 weeks' gestation: comparison of survival and neonatal and two-year morbidity. Obstet Gynecol 1985; 66:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/20\">",
"      Jonas HA, Khalid N, Schwartz SM. The relationship between Caesarean section and neonatal mortality in very-low-birthweight infants born in Washington State, USA. Paediatr Perinat Epidemiol 1999; 13:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/21\">",
"      Jonas HA, Lumley JM. The effect of mode of delivery on neonatal mortality in very low birthweight infants born in Victoria, Australia: Caesarean section is associated with increased survival in breech-presenting, but not vertex-presenting, infants. Paediatr Perinat Epidemiol 1997; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/22\">",
"      Riskin A, Riskin-Mashiah S, Lusky A, et al. The relationship between delivery mode and mortality in very low birthweight singleton vertex-presenting infants. BJOG 2004; 111:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/23\">",
"      Reddy UM, Zhang J, Sun L, et al. Neonatal mortality by attempted route of delivery in early preterm birth. Am J Obstet Gynecol 2012; 207:117.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/24\">",
"      Reddy UM, Zhang J, Sun L, et al. Neonatal mortality by attempted route of delivery in early preterm birth. Am J Obstet Gynecol 2012; 117:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/25\">",
"      Lee HC, Gould JB. Survival advantage associated with cesarean delivery in very low birth weight vertex neonates. Obstet Gynecol 2006; 107:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/26\">",
"      Lee HC, Gould JB. Survival rates and mode of delivery for vertex preterm neonates according to small- or appropriate-for-gestational-age status. Pediatrics 2006; 118:e1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/27\">",
"      Deulofeut R, Sola A, Lee B, et al. The impact of vaginal delivery in premature infants weighing less than 1,251 grams. Obstet Gynecol 2005; 105:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/28\">",
"      Malloy MH. Impact of cesarean section on neonatal mortality rates among very preterm infants in the United States, 2000-2003. Pediatrics 2008; 122:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/29\">",
"      Wylie BJ, Davidson LL, Batra M, Reed SD. Method of delivery and neonatal outcome in very low-birthweight vertex-presenting fetuses. Am J Obstet Gynecol 2008; 198:640.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/30\">",
"      Batton B, Burnett C, Verhulst S, Batton D. Extremely preterm infant mortality rates and cesarean deliveries in the United States. Obstet Gynecol 2011; 118:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/31\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/32\">",
"      Riskin A, Riskin-Mashiah S, Bader D, et al. Delivery mode and severe intraventricular hemorrhage in single, very low birth weight, vertex infants. Obstet Gynecol 2008; 112:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/33\">",
"      Richmond JR, Morin L, Benjamin A. Extremely preterm vaginal breech delivery en caul. Obstet Gynecol 2002; 99:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/34\">",
"      Goldenberg RL, Nelson KG. The unanticipated breech presentation in labor. Clin Obstet Gynecol 1984; 27:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/35\">",
"      Qiu H, Paneth N, Lorenz JM, Collins M. Labor and delivery factors in brain damage, disabling cerebral palsy, and neonatal death in low-birth-weight infants. Am J Obstet Gynecol 2003; 189:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/36\">",
"      Bishop EH, Israel SL, Briscoe CC. Obstetric influences on the premature infant's first year of development. A report from the collaborative study of cerebral palsy. Obstet Gynecol 1965; 26:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/37\">",
"      de Crespigny LC, Robinson HP. Can obstetricians prevent neonatal intraventricular haemorrhage? Aust N Z J Obstet Gynaecol 1983; 23:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/38\">",
"      Lobb MO, Duthie SJ, Cooke RW. The influence of episiotomy on the neonatal survival and incidence of periventricular haemorrhage in very-low-birth-weight infants. Eur J Obstet Gynecol Reprod Biol 1986; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/39\">",
"      The TG. Is routine episiotomy beneficial in the low birth weight delivery? Int J Gynaecol Obstet 1990; 31:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20374/abstract/40\">",
"      Schwartz DB, Miodovnik M, Lavin JP Jr. Neonatal outcome among low birth weight infants delivered spontaneously or by low forceps. Obstet Gynecol 1983; 62:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4444 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20374=[""].join("\n");
var outline_f19_57_20374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAPARTUM ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1398691850\">",
"      Hospital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pediatric referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Maternal analgesia/anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MODE OF DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cesarean versus vaginal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Episiotomy and forceps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4444|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/23/379\" title=\"table 1\">",
"      Preterm umbilical cord gases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=related_link\">",
"      Delivery of the fetus in breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=related_link\">",
"      Procedure for vacuum assisted operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=related_link\">",
"      Umbilical cord blood acid-base analysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20375="Argatroban: Drug information";
var content_f19_57_20375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Argatroban: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30995?source=see_link\">",
"    see \"Argatroban: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"    see \"Argatroban: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant, Thrombin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of thrombosis (heparin-induced thrombocytopenia):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     2 mcg/kg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetics and pharmacodynamics have not been evaluated prospectively in obese patients; however, retrospective data suggests using actual body weight to dose and that adjustment of initial dose is unnecessary in obesity (BMI up to 51 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )  (Rice, 2007); weight range included in phase II and III clinical trials: 33-204 kg (actual body weight).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     Patient may not be at steady-state but measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5-3 times the initial baseline value, not exceeding 100 seconds; dosage should not exceed 10 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Critically-ill patients with normal hepatic function have become excessively anticoagulated with FDA-approved or lower starting doses of argatroban. Doses between 0.15-1.3 mcg/kg/minute were required to maintain aPTTs in the target range (Reichert, 2003). In a prospective observational study of critically-ill patients with multiple organ dysfunction (MODS) and suspected or proven HIT, an initial infusion dose of 0.2 mcg/kg/minute was found to be sufficient and safe in this population (Beiderlinden, 2007). Consider reducing starting dose to 0.2 mcg/kg/minute in critically-ill patients with MODS defined as a minimum number of two organ failures. Another report of a cardiac patient with anasarca secondary to acute renal failure had a reduction in argatroban clearance similar to patients with hepatic dysfunction. Reduced clearance may have been due to reduced liver perfusion (de Denus, 2003). The American College of Chest Physicians has recommended an initial infusion rate of 0.5-1.2 mcg/kg/minute for patients with heart failure, MODS, severe anasarca, or postcardiac surgery (Linkins, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion to oral anticoagulant:",
"     </i>",
"     Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients receiving &le;2 mcg/kg/minute of argatroban: Argatroban therapy can be stopped when the combined INR on warfarin and argatroban is &gt;4; repeat INR measurement in 4-6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients receiving &gt;2 mcg/kg/minute of argatroban: In order to predict the INR on warfarin alone, reduce dose of argatroban to 2 mcg/kg/minute; measure INR for argatroban and warfarin 4-6 hours after dose reduction; argatroban therapy can be stopped when the combined INR on warfarin and argatroban is &gt;4. Repeat INR measurement in 4-6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians suggests monitoring chromogenic factor X assay when transitioning from argatroban to warfarin (Garcia, 2012) or overlapping administration of warfarin for a minimum of 5 days until INR is within target range; recheck INR after anticoagulant effect of argatroban has dissipated (Guyatt, 2012). Factor X levels &lt;45% have been associated with INR values &gt;2 after the effects of argatroban have been eliminated (Arpino, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Prefilter administration for continuous renal replacement therapy (CRRT) in critically-ill patients with HIT (unlabeled use; Link, 2009):",
"     </b>",
"     0.1-1.5 mcg/kg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     Loading dose of 100 mcg/kg was administered during clinical trial; however, this may be unnecessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Percutaneous coronary intervention (PCI):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     Begin infusion of 25 mcg/kg/minute and administer bolus dose of 350 mcg/kg (over 3-5 minutes). ACT should be checked 5-10 minutes after bolus infusion; proceed with procedure if ACT &gt;300 seconds.",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetics and pharmacodynamics have not been evaluated prospectively in obese patients; however, retrospective data suggests using actual body weight to dose and that adjustment of initial dose is unnecessary in obesity (BMI up to 51 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) (Hursting, 2008); weight range included in phase II and III clinical trials: 49-141 kg (actual body weight).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Following initial bolus:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ACT &lt;300 seconds: Give an additional 150 mcg/kg bolus, and increase infusion rate to 30 mcg/kg/minute (recheck ACT in 5-10 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ACT &gt;450 seconds: Decrease infusion rate to 15 mcg/kg/minute (recheck ACT in 5-10 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once a therapeutic ACT (300-450 seconds) is achieved, infusion should be continued at this dose for the duration of the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If dissection, impending abrupt closure, thrombus formation during PCI, or inability to achieve ACT &gt;300 seconds:",
"     </i>",
"     An additional bolus of 150 mcg/kg, followed by an increase in infusion rate to 40 mcg/kg/minute may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Post-PCI anticoagulation, if required, may be achieved by continuing infusion at a reduced dose of 2-10 mcg/kg/minute, with close monitoring of aPTT.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6273425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"      see \"Argatroban: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Heparin-induced thrombocytopenia",
"     </b>",
"     (dosing based on limited data from critically-ill patients): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial dose: 0.75 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance dose: Patient may not be at steady-state but measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5-3 times the initial baseline value, not exceeding 100 seconds; dosage may be adjusted in increments of 0.1-0.25 mcg/kg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     Frequent dosage adjustments may be required to maintain desired anticoagulant activity.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F136549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Removal during hemodialysis and continuous venovenous hemofiltration is clinically insignificant. No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F136550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased clearance and increased elimination half-life are seen with hepatic impairment; dose should be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial dose: 0.2 mcg/kg/minute; adjust dose in increments of &le;0.05 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Per manufacturer labeling, the initial dose for moderate-to-severe hepatic impairment (Child-Pugh classes B and C) is 0.5 mcg/kg/minute; monitor aPTT closely and adjust dose as necessary. However, patients with severe hepatic impairment (Child-Pugh class C) may require further reduction of the initial dose. One case report describes a dose of 0.05 mcg/kg/minute required to maintain a stable, therapeutic aPTT in a patient with severe hepatic impairment (Yarbrough, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     During PCI, avoid use in patients with elevations of ALT/AST (&ge;3 times ULN); the use of argatroban in these patients has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 125 mg (125 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in water for injection: 50 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 100 mg/mL (2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The 2.5 mL (100 mg/mL)",
"     <b>",
"      concentrated",
"     </b>",
"     vial",
"     <b>",
"      must be diluted to 1 mg/mL",
"     </b>",
"     prior to administration. The premixed 50 mL or 125 mL (1 mg/mL) vial requires no further dilution. The premixed 1 mg/mL vial may be inverted for use with an infusion set.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     250 mg in 250 mL (concentration: 1000",
"     <b>",
"      mcg",
"     </b>",
"     /mL) in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F639171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab, atropine, diltiazem, diphenhydramine, dobutamine, dopamine, eptifibatide, fentanyl, hydrocortisone sodium succinate, metoprolol, midazolam, morphine, norepinephrine, phenylephrine, tirofiban, verapamil.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT); adjunct to percutaneous coronary intervention (PCI) in patients who have or are at risk of thrombosis associated with HIT",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6826883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To maintain extracorporeal circuit patency (prefilter administration) of continuous renal replacement therapy (CRRT) in critically-ill patients with HIT",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F136573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Argatroban may be confused with Aggrastat&reg;, Orgaran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect of argatroban. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (PCI related: &lt;1% to 15%), hypotension (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal bleed (major: &lt;1% to 3%; minor: 3% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Genitourinary bleed and hematuria (major: &lt;1%; minor: 2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (1% to 10%), cardiac arrest (6%), ventricular tachycardia (5%), bradycardia (5%), myocardial infarction (PCI: 4%), atrial fibrillation (3%), angina (2%), CABG-related bleeding (minor, 2%), myocardial ischemia (2%), cerebrovascular disorder (&lt;1% to 2%), thrombosis (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (&lt;1% to 7%), headache (5%), pain (5%), intracranial bleeding (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin reactions (bullous eruption, rash; 1% to &lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5% to 7%), diarrhea (6%), vomiting (4% to 6%), abdominal pain (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased (&lt;2 g/dL), hematocrit decreased (minor: 2% to 10%; major: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Bleeding at injection or access site (minor: 2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (PCI related: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Abnormal renal function (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (8% to 10%), cough (3% to 10%), hemoptysis (minor: &lt;1% to 3%), pneumonia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (6%), infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, constipation (infants and children), GERD, hypokalemia (infants and children), limb and below-the-knee stump bleed, multisystem hemorrhage and DIC, pulmonary edema, retroperitoneal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to argatroban or any component of the formulation; overt major bleeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: The most common complication is bleeding. Certain patients are at increased risk of bleeding; risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; recent puncture of large vessels or organ biopsy; recent CVA, stroke, intracerebral surgery, or other neuraxial procedure; severe uncontrolled hypertension; renal impairment; recent major surgery; recent major bleeding (intracranial, GI, intraocular, or pulmonary). Monitor for signs and symptoms of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may require &gt;4 hours to achieve full reversal of argatroban's anticoagulant effect following treatment. Avoid use during PCI in patients with elevations of ALT/AST (&ge;3 times ULN); use in these patients has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral anticoagulants: Discontinue all parenteral anticoagulants prior to starting therapy; allow reversal of heparin's effects before initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombolytic agents: Safety and efficacy for use with thrombolytic agents has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Argatroban prolongs the PT/INR. Concomitant use with warfarin will cause increased prolongation of the PT and INR greater than that of warfarin alone. If warfarin is initiated concurrently with argatroban, initial PT/INR goals while on argatroban may require modification; alternative guidelines for monitoring therapy should be followed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Critically-ill patients: Use with caution in critically-ill patients; reduced clearance may require dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Limited pharmacokinetic and dosing information is available following use in critically-ill children with heparin-induced thrombocytopenia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F136560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies. Information related to argatroban in pregnancy is limited. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F136532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if argatroban is excreted in human milk. Because of the serious potential of adverse effects to the nursing infant, a decision to discontinue nursing or discontinue argatroban should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F136530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Argatroban Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/50 mL (50 mL): $272.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (2.5 mL): $1576.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obtain baseline aPTT prior to start of therapy. Patient may not be at steady-state but check aPTT 2 hours after start of therapy to adjust dose, keeping the steady-state aPTT 1.5-3 times the initial baseline value (not exceeding 100 seconds). Monitor hemoglobin, hematocrit, signs and symptoms of bleeding.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     PCI: Monitor ACT before dosing, 5-10 minutes after bolus dosing, and after any change in infusion rate and at the end of the procedure. Additional ACT assessments should be made every 20-30 minutes during extended PCI procedures.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arganova (NL);",
"     </li>",
"     <li>",
"      Argata (AT);",
"     </li>",
"     <li>",
"      Argatra (DE);",
"     </li>",
"     <li>",
"      Da Bei (CL);",
"     </li>",
"     <li>",
"      Novastan (CL, DK, IT, JP, KP, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A direct, highly-selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 174 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Albumin: 20%; &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via hydroxylation and aromatization. Metabolism via CYP3A4/5 to four known metabolites plays a minor role. Unchanged argatroban is the major plasma component. Plasma concentration of metabolite M1 is 0% to 20% of the parent drug and is three- to fivefold weaker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 39-51 minutes; Hepatic impairment: &le;181 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Steady-state: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (65%); urine (22%); low quantities of metabolites M2-4 in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance is decreased in critically-ill pediatric patients",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arpino PA, Demirjian Z, and Van Cott EM, &ldquo;Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(2):157-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/15767231/pubmed\" id=\"15767231\" target=\"_blank\">",
"        15767231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baghdasarian SB, Singh I, Militello MA, et al, &ldquo;Argatroban Dosage in Critically Ill Patients With HIT,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      2004, 104:1779 [abstract 1779 from 2004 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beiderlinden M, Treschan TA, Gorlinger K, et al, &ldquo;Argatroban Anticoagulation in Critically Ill Patients,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(5):749-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/17440009/pubmed\" id=\"17440009\" target=\"_blank\">",
"        17440009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE and White RH, &ldquo;Pharmacotherapy of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2003, 4(6):919-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/12783589/pubmed\" id=\"12783589\" target=\"_blank\">",
"        12783589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(9):1237-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/12921506/pubmed\" id=\"12921506\" target=\"_blank\">",
"        12921506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Honisko ME, Fink JM, Militello MA, et al, &ldquo;Compatibility of Argatroban With Selected Cardiovascular Agents,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(22):2415-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/15581266/pubmed\" id=\"15581266\" target=\"_blank\">",
"        15581266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hursting NJ and Jang IK, \"Impact of Renal Function on Argatroban Therapy During Percutaneous Coronary Intervention,\"",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2010 29(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/19504050/pubmed\" id=\"19504050\" target=\"_blank\">",
"        19504050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine RL, Hursting MJ, and McCollum D, \"Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2006, 129(5):1167-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/16685006/pubmed\" id=\"16685006\" target=\"_blank\">",
"        16685006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis BE, Matthai WH, Cohen M, et al, &ldquo;Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2002, 57(2):177-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/12357516/pubmed\" id=\"12357516\" target=\"_blank\">",
"        12357516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis BE, Wallis DE, Berkowitz SD, et al, &ldquo;Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(14):1838-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/11294800/pubmed\" id=\"11294800\" target=\"_blank\">",
"        11294800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Link A, Girndt M, Selejan S, et al, &ldquo;Argatroban for Anticoagulation in Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(1):105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/19050602/pubmed\" id=\"19050602\" target=\"_blank\">",
"        19050602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linkins L, Dans AL, Moores LK, et al, &ldquo;Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e495-530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/22315270/pubmed\" id=\"22315270\" target=\"_blank\">",
"        22315270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray PT, Reddy BV, Grossman EJ, et al, &ldquo;A Prospective Comparison of Three Argatroban Treatment Regimens During Hemodialysis in End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 2004, 66(6):2446-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/15569338/pubmed\" id=\"15569338\" target=\"_blank\">",
"        15569338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reichert MG, MacGregor DA, Kincaid EH, et al, &ldquo; Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(5):652-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/12708939/pubmed\" id=\"12708939\" target=\"_blank\">",
"        12708939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rice L, Hursting MJ, Baillie GM, et al, &ldquo;Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(8):1028-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/17525167/pubmed\" id=\"17525167\" target=\"_blank\">",
"        17525167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tang IY, Cox DS, Patel K, et al, &ldquo;Argatroban and Renal Replacement Therapy in Patients With Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(2):231-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/15632219/pubmed\" id=\"15632219\" target=\"_blank\">",
"        15632219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yarbrough PM, Varedi A, Walker A, et al, &ldquo;Argatroban Dose Reductions for Suspected Heparin-Induced Thrombocytopenia Complicated by Child-Pugh Class C Liver Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2012,46(11):e30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/57/20375/abstract-text/23073302/pubmed\" id=\"23073302\" target=\"_blank\">",
"        23073302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8765 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20375=[""].join("\n");
var outline_f19_57_20375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136565\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136547\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6273425\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136548\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136549\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136550\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136522\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136507\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136524\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471317\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471318\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639171\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136523\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6826883\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136573\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136563\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136527\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136511\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136560\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136515\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136518\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136531\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136554\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136532\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136530\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136520\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539819\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136510\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136526\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30995?source=related_link\">",
"      Argatroban: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=related_link\">",
"      Argatroban: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20376="Mixed osteodystrophy";
var content_f19_57_20376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micrograph showing mixed uremic osteodystrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone biopsy in mixed uremic osteodystrophy which is characterized by features of both osteitis fibrosa and low turnover osteomalacia. Left panel: Trichrome stain reveals increased numbers of multinucleate osteoclasts (short arrow) as expected in osteitis fibrosa plus a marked increase in adjacent nonmineralized osteoid in red-brown (long arrow). Right panel: Tetracycline labeling demonstrates impaired mineralization as evidenced by diffuse tetracycline deposition (yellow stain, short arrow) and the absence of tetracycline at some bone forming surfaces as in the lower left quadrant (long arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Darryl Quarles, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Micrograph showing normal bone histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic appearance of normal bone.",
"    <br>",
"     (Left panel) Goldner Masson trichrome stain shows mineralized lamellar bone in blue and adjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25 percent of bone surfaces. The cellular area between the osseous structures is the marrow space.",
"     <br>",
"      (Right panel) Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, and tetracycline markers appear as luminescent yellow-green bands within bone and beneath osteoid (arrow). The distinct dual bands represent active mineralized bone formation.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of L Darryl Quarles, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20376=[""].join("\n");
var outline_f19_57_20376=null;
var title_f19_57_20377="Initial management of animal and human bites";
var content_f19_57_20377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of animal and human bites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20377/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20377/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20377/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20377/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/57/20377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/57/20377/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/57/20377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and human bites are a common problem. Proper care requires wound inspection for injury to deeper structures; meticulous wound care at the initial encounter; and decisions regarding primary closure, the provision of prophylactic antibiotics for wounds at high risk for infection, and prophylaxis for tetanus and rabies as indicated.",
"   </p>",
"   <p>",
"    The clinical manifestations, wound care, and initial management of animal and human bites in children and adults will be discussed here. The microbiology and infectious disease aspects of human, cat, and dog bites is covered in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal bites are common. In the United States, there is an annual incidence of two to five million occurrences which account for about 1 percent of all visits to emergency departments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. More than one million victims of bites seek medical attention; medical costs for dog bites alone are estimated at $4165 million per year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/6\">",
"     6",
"    </a>",
"    ]. The vast majority of mammalian bites are inflicted by dogs (60 to 90 percent), with the remainder caused by cats (5 to 20 percent), rodents (2 to 3 percent), humans (2 to 3 percent), and rarely, other animals.",
"   </p>",
"   <p>",
"    Approximately 10 percent of bite wounds presenting for medical attention require suturing and follow-up care, and 1 to 2 percent result in hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/3,7-9\">",
"     3,7-9",
"    </a>",
"    ]. Animal bites cause 10 to 20 deaths annually in the United States, primarily among infants and small children. Extensive morbidity, including disability and cosmetic damage, can also result from infection.",
"   </p>",
"   <p>",
"    Epidemiology differs between dog and cat bites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dog bites",
"      </strong>",
"      &mdash; Dog bites are frequently caused by animals known to the victim. This was demonstrated in a large observational study that described dog bite wounds sustained by children who were treated in an Austrian pediatric trauma center [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/10\">",
"       10",
"      </a>",
"      ]. The dog was familiar to the child in 82 percent of cases. German Shepherds were responsible for 34 percent of bites, although the breed comprised only 12 percent of the local dog population.",
"      <br/>",
"      <br/>",
"      In other studies, male dogs and certain breeds of dog (eg, German Shepherds, Pit Bull Terriers) are more commonly associated with bites [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/4,10\">",
"       4,10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Dog bites to the head and neck occur in 60 to 70 percent of attacks in children below the age of five years and in 50 percent of those 5 to 10 years old, presumably because of the proximity of the young child's head to the level of the mouth in a large dog and their uninhibited behavior around dogs [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/11\">",
"       11",
"      </a>",
"      ]. In the Austrian series, 50 percent of injuries were to the face, head, and neck [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cat bites",
"      </strong>",
"      &mdash; Cats usually cause wounds with their teeth or claws. In contrast to dog bites, which often occur in males and children without overt provocation, females and adults are more commonly bitten by cats; 89 percent of these bites are provoked [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant pathogens in animal bite wounds are the oral flora of the biting animal and human skin flora. Infection usually results from a mixture of organisms. Common pathogens (in order of prevalence) include Pasteurella species, staphylococci, streptococci, and anaerobic bacteria. Capnocytophaga canimorsus, a fastidious gram-negative rod, can cause bacteremia and fatal sepsis after animal bites, especially in asplenic patients, chronic alcohol abusers, or those with underlying hepatic disease. Cat bites can also transmit Bartonella henselae, the organism responsible for cat scratch disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H3#H3\">",
"     \"Soft tissue infections due to dog and cat bites\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link\">",
"     \"Pasteurella infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogens involved in human bite wound infections usually reflect normal human mouth and skin flora. The types of organisms recovered differ from animal bites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      P. multocida is a rare isolate.",
"     </li>",
"     <li>",
"      Eikenella corrodens, a gram-negative anaerobe, is a common constituent of normal human mouth flora and is recovered from seven to 29 percent of human bite wounds but rarely from animal bites.",
"     </li>",
"     <li>",
"      Aerobic gram-positive cocci (eg, Group A Streptococcus) and anaerobes are found more frequently in bites from humans than from other animals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H2#H2\">",
"       \"Soft tissue infections due to human bites\", section on 'Microbiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical location and nature of the injury differs depending upon the animal inflicting the bite:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dog bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dog bites cause a range of injuries from minor wounds (eg, scratches, abrasions) to major complicated wounds (eg, deep open lacerations, deep puncture wounds, tissue avulsions and crush injuries) (",
"    <a class=\"graphic graphic_picture graphicRef56399 \" href=\"UTD.htm?1/2/1057\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. The jaws of large dogs can exert a strong force that may inflict serious injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/14\">",
"     14",
"    </a>",
"    ]. Lethal injuries, although rare, usually involve the head and neck, or direct penetration of vital organs in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extremities, particularly the dominant hand, are the most frequent site of injury when older children or adults are bitten by a dog [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cat bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-thirds of cat bites involve the upper extremities; scratches typically occur on the upper extremities or face. Deep puncture wounds are of particular concern because cats have long, slender, sharp teeth. When the hand is the target of such a puncture wound, bacteria can be inoculated below the periosteum or into a joint and result in osteomyelitis or septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/14,17\">",
"     14,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Human bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient is bitten by another human, a semicircular or oval area of erythema or bruising is usually visible; the skin itself may or may not be intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pediatric wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children, human bites are typically located on the face, upper extremities, or trunk. They frequently occur as the result of aggressive play with another child who inflicts the bite. These wounds may not break the skin and are often trivial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/18\">",
"     18",
"    </a>",
"    ]. However, if a bite mark has an intercanine distance greater than three centimeters, the bite probably came from an adult and should raise concerns about child abuse (",
"    <a class=\"graphic graphic_picture graphicRef69917 \" href=\"UTD.htm?27/4/27712\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Self-inflicted bites may also occur from nail-biting and thumb-sucking but can also be associated with psychiatric illness or metabolic disease. Occasionally, paronychia in infants has been reported to result from a parent biting rather than cutting the child's nails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clenched fist injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human bites in adolescents and adults frequently present with small wounds overlying the metacarpophalangeal joints; these wounds arise from a fist fight when the individual throwing a punch with a clenched fist meets the teeth of another person. Skin breaks over the knuckles can lead to the introduction of both skin and oral flora into fascial layers of the hand with potential spread to the nearby joint [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lacerations typically occur over the third and fourth metacarpophalangeal or proximal interphalangeal joints of the dominant hand. Although they are usually quite small (up to 15 mm), they are highly prone to infection given the proximity of the skin over the knuckles to the joint capsule. Relaxation of the fist may carry organisms into the deep compartments and the deep tendon spaces of the hand. Thus, patients with such injuries are at risk for deep soft tissue infection, septic arthritis, and osteomyelitis.",
"   </p>",
"   <p>",
"    Many patients ignore these wounds until the onset of pain, swelling or purulent discharge; as a result, these injuries are often complicated by established infection at the time patients seek medical attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H3#H3\">",
"     \"Soft tissue infections due to human bites\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bites to the breasts and genitals may occur during sexual activity or sexual assault.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infected wound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of bite wound infections may include fever, erythema, swelling, tenderness, purulent drainage and lymphangitis (",
"    <a class=\"graphic graphic_picture graphicRef74167 \" href=\"UTD.htm?34/3/34879\">",
"     picture 3",
"    </a>",
"    ). Complications include subcutaneous abscesses, osteomyelitis, septic arthritis, tendonitis, and bacteremia.",
"   </p>",
"   <p>",
"    Infection with Pasteurella multocida characteristically develops rapidly following cat or dog bites with erythema, swelling, and intense pain evident as early as 12 to 24 hours after the bite. Systemic signs of infection, such as fever and lymphadenopathy, are infrequent. Localized cellulitis caused by this organism can be subacute in onset, beginning 24 to 72 hours after the injury; systemic infection occurs in fewer than 20 percent of these cases, but may involve the bone, joints, blood, and meninges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link&amp;anchor=H4#H4\">",
"     \"Pasteurella infections\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A delay in treatment from the time of bite injury is one of several factors that can affect the incidence of infection following dog or cat bite [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients who wait more than 24 hours after injury to seek medical attention have probably developed infection and are often seeking care for infectious signs or symptoms rather than evaluation of an uninfected wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerobic and anaerobic blood cultures are warranted prior to antibiotic therapy in patients with an infected bite wound and signs of systemic infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Infected wound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A complete white blood cell count, C-reactive protein, and erythrocyte sedimentation rate may be elevated in patients with cellulitis, joint infection, osteomyelitis, or sepsis, but normal values do not rule out these infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Wound culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound cultures of uninfected bite wounds are not useful [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/22\">",
"     22",
"    </a>",
"    ]. If a bite wound appears to be infected, Gram stain and aerobic and anaerobic cultures should be obtained prior to the initiation of antibiotics. The laboratory requisition should note that an animal or human bite wound is the culture source. Eikenella corrodens (human bites) and Pasteurella multocida (dog and cat bites) are fastidious organisms and are often misidentified.",
"   </p>",
"   <p>",
"    Wound cultures are NOT indicated in clinically uninfected bite wounds as results do not correlate with likelihood of infection or the pathogen that is present in patients with subsequent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/8,23\">",
"     8,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Plain radiographs and ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep bite wounds near joints warrant AP and lateral plain radiographs to evaluate for disruption of bone or joints and evidence of foreign bodies, such as embedded teeth.",
"   </p>",
"   <p>",
"    Plain radiographs are also indicated in markedly infected wounds to detect bony and soft tissue injury, subcutaneous gas, and changes associated with osteomyelitis (",
"    <a class=\"graphic graphic_picture graphicRef68154 \" href=\"UTD.htm?1/10/1185\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link&amp;anchor=H11#H11\">",
"     \"Hematogenous osteomyelitis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound may be helpful for identifying abscess formation as well as locating radiolucent foreign bodies in infected wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Head computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dog bites to the head occasionally penetrate the skull. A depressed skull fracture, local infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brain abscess may result [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Thus, a head computed tomographic (CT) scan is warranted in patients with a deep dog bite to the scalp, including puncture wounds, especially in infants less than two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/26\">",
"     26",
"    </a>",
"    ]. The following radiographic findings indicate a penetrating injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture",
"     </li>",
"     <li>",
"      Puncture through the outer plate of the skull",
"     </li>",
"     <li>",
"      Free air in the cranial vault",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct pressure should be applied to actively bleeding wounds and a neurovascular assessment should be performed in areas distal to the wound. Deep wounds to vital structures should be treated as major penetrating trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\", section on 'Approach to penetrating trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Wound preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meticulous wound care constitutes one of the most important steps in treating a laceration due to an animal or human bite. It is less clear how much wound preparation reduces the risk of infection after puncture wounds. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Puncture wounds'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Appropriate local anesthesia facilitates adequate wound cleansing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To reduce the counts of bacteria present in the wound, the surface should be cleaned with 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    or 1 percent benzalkonium chloride, and the depths irrigated with copious amounts of saline using pressure irrigation. Debridement of devitalized tissue is important to remove any nidus for infection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once anesthetized, the wound should be carefully explored to identify injury to underlying structures and the possible presence of a foreign body. Wounds over or near the metacarpophalangeal joints should be explored carefully in the anatomical AND the clenched-fist position to assess for damage to the underlying tendon sheath, fascia, joint capsule, and metacarpal head. If a potentially deep bite occurs near a bone or if a foreign body might be present, appropriate imaging should be obtained (eg, plain radiograph or ultrasound).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Puncture wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Puncture wounds present significant challenges to wound care. No wound treatment method has been proven to effectively reduce contamination or subsequent infection of these wounds. Most research involves the care of plantar puncture wounds caused by stepping on a sharp object rather than puncture wounds caused by bites.",
"   </p>",
"   <p>",
"    The following approach is based upon clinical experience and biologic reasoning [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trim any superficial devitalized epidermal tissue",
"     </li>",
"     <li>",
"      Inspect the wound for evidence of deep puncture, especially if the wound is located in the scalp or near a joint",
"     </li>",
"     <li>",
"      Remove any foreign bodies or gross wound contaminants",
"     </li>",
"     <li>",
"      Superficially irrigate the wound, avoiding high pressure irrigation into the wound",
"     </li>",
"     <li>",
"      Avoid removal of deep tissue (eg, \"coring\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of soaking puncture wounds in an antiseptic solution (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    ) is controversial. While some experts suggest that it promotes wound cleansing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/27\">",
"     27",
"    </a>",
"    ], others avoid this approach because of the potential to delay wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/28\">",
"     28",
"    </a>",
"    ]. We suggest soaking puncture wounds in an antiseptic solution for up to 15 minutes after the above steps are performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to wound closure varies in part with the type of bite. A clinician with prior training and experience in laceration repair may perform primary wound closure of simple lacerations due to dog bites. In contrast, most cat or human bites are left open to heal by secondary intention. However, when cosmesis is paramount (eg, facial lacerations), the experienced clinician may choose to repair these wounds as well.",
"   </p>",
"   <p>",
"    In addition to these indications for primary wound closure of open lacerations, we suggest that the laceration meets ALL of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinically uninfected",
"     </li>",
"     <li>",
"      Less than 12 hours old (24 hours on the face)",
"     </li>",
"     <li>",
"      NOT located on the hand or foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In particular, wounds to the face are usually closed promptly because good cosmesis is especially important, and infection of these wounds is uncommon, perhaps due to the excellent blood supply to the face and scalp. Subcutaneous sutures should be used sparingly, if at all, since foreign material in a contaminated wound increases the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Wound preparation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Provision of proper wound care is essential to good outcomes and to reducing infection risk in patients who undergo wound closure. When bite wounds are sutured, extensive irrigation, debridement, avoidance of deep sutures (if possible), institution of prophylactic antibiotic therapy, and close follow-up are indicated. In contrast, sealing the wound with cyanoacrylate tissue adhesive (\"glue\") should be AVOIDED.",
"   </p>",
"   <p>",
"    Wounds at high risk for the development of infection should NOT be closed primarily in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/3,5,8,29,30\">",
"     3,5,8,29,30",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crush injuries",
"     </li>",
"     <li>",
"      Puncture wounds",
"     </li>",
"     <li>",
"      Bites involving the hands and feet (",
"      <a class=\"graphic graphic_picture graphicRef74167 \" href=\"UTD.htm?34/3/34879\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wounds more than 12 hours old (24 hours old on face)",
"     </li>",
"     <li>",
"      Cat or human bites, except those to the face",
"     </li>",
"     <li>",
"      Bite wounds in compromised hosts (eg, immunocompromised, absent spleen or splenic dysfunction, venous stasis, diabetes mellitus [adults])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such wounds should be irrigated copiously, dressed, left open to drain, and examined daily to detect signs of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Risk of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have addressed the risk of infection following primary closure of bite wounds:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a quasi-randomized trial of 96 patients with 169 dog bite wounds, 92 were closed and 77 left open after debridement and thorough irrigation; prophylactic antibiotics were not given [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/31\">",
"       31",
"      </a>",
"      ]. Thirteen wounds developed infection; the rate did not differ based upon whether the wound was sutured or remained open (7.6 versus 7.8 percent).",
"     </li>",
"     <li>",
"      An observational study assessed wound infection in 145 bites that were closed primarily: 88 bites were inflicted by dogs, 45 by cats, and 12 by humans [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/32\">",
"       32",
"      </a>",
"      ]. The majority of the wounds (57 percent) were on the head and neck. Eight patients (5.5 percent) developed infection despite having received antibiotics at a mean of two hours post-injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Delayed primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some physicians choose to leave bite wounds open for drainage and possible delayed primary closure 72 hours after the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/8\">",
"     8",
"    </a>",
"    ]. Wound cleansing and debridement of devitalized tissue should still occur during initial care, and the wound should be dressed with wet saline dressings twice daily until closure is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Surgical consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical consultation is usually necessary for the following wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep wounds that penetrate bone, tendons, joints, or other major structures",
"     </li>",
"     <li>",
"      Complex facial lacerations",
"     </li>",
"     <li>",
"      Wounds associated with neurovascular compromise",
"     </li>",
"     <li>",
"      Wounds with complex infections (eg, abscess formation, osteomyelitis, or joint infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics reduce the rate of infection due to some animal bites, especially cat bites. Although routine antibiotic prophylaxis is not recommended, prophylaxis is warranted in certain high-risk wounds . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H8#H8\">",
"     \"Soft tissue infections due to dog and cat bites\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep puncture wounds (especially due to cat bites)",
"     </li>",
"     <li>",
"      Moderate to severe wounds with associated crush injury",
"     </li>",
"     <li>",
"      Wounds in areas of underlying venous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphatic compromise",
"     </li>",
"     <li>",
"      Wounds on the hand(s), genitalia, face, or in close proximity to a bone or joint (particularly the hand and prosthetic joints)",
"     </li>",
"     <li>",
"      Wounds requiring closure",
"     </li>",
"     <li>",
"      Bite wounds in compromised hosts (eg, immunocompromised, absent spleen or splenic dysfunction, and adults with diabetes mellitus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Human bites in children are typically trivial and do not require antibiotic prophylaxis. However, prophylaxis should be provided to human bites through the dermis, especially wounds to the hand, because of the higher risk of infection. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Human bites'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H7#H7\">",
"     \"Soft tissue infections due to human bites\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If patients are to receive antimicrobial prophylaxis, the first dose should be given as soon as possible after the injury. Some physicians prefer to give the initial dose parenterally to rapidly obtain effective tissue levels in patients with cat or dog bites (",
"    <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"     table 1",
"    </a>",
"    ) or human bites (",
"    <a class=\"graphic graphic_table graphicRef80019 \" href=\"UTD.htm?43/40/44684\">",
"     table 2",
"    </a>",
"    ). Oral antibiotics may subsequently be given for three to five days following initial treatment of dog or cat bites (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 3",
"    </a>",
"    ) or human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H8#H8\">",
"     \"Soft tissue infections due to dog and cat bites\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H7#H7\">",
"     \"Soft tissue infections due to human bites\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Tetanus and rabies prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus and rabies prophylaxis should be provided as indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetanus &ndash; Animal and human bites are tetanus prone wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/9,33\">",
"       9,33",
"      </a>",
"      ]. The patient's tetanus immunization status should be determined for any bite wound that breaks the skin. Tetanus toxoid, DTaP, or Td should be administered during the first encounter in patients as indicated (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 5",
"      </a>",
"      ). The need for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"       tetanus immune globulin",
"      </a>",
"      (TIG) should also be assessed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rabies &ndash; Rabies is a frequent concern with animal bites, especially when the attack is unprovoked or the animal appears ill, is wild, or is a stray. In the United States, the Centers for Disease Control provides guidance regarding the risk for rabies and the need for post-exposure prophylaxis based on type of animal exposure at",
"      <a class=\"external\" href=\"file://www.cdc.gov/rabies/exposure/index.html\">",
"       file://www.cdc.gov/rabies/exposure/index.html",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bites, scratches, abrasions, or contact with animal saliva via mucous membranes or a break in the skin all can transmit rabies. Early wound cleansing is an important prophylactic measure in addition to timely administration of rabies immune globulin and vaccine (",
"    <a class=\"graphic graphic_table graphicRef70600 \" href=\"UTD.htm?27/43/28347\">",
"     table 6",
"    </a>",
"    ). Indications for rabies prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link&amp;anchor=H19#H19\">",
"     \"Rabies immune globulin and vaccine\", section on 'Dosing schedules and routes of administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link&amp;anchor=H8#H8\">",
"     \"When to use rabies prophylaxis\", section on 'Types of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Viral prophylaxis after human bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any unvaccinated patient or individual negative for anti-HBs antibodies who is bitten by an individual positive for HBsAg should receive both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef59736 \" href=\"UTD.htm?20/39/21116\">",
"     table 7",
"    </a>",
"    ). If the source is unknown or not available for testing, the clinician should initiate the hepatitis B vaccine series. Individuals who work in facilities where the risk for human bites is high, such as institutions for the cognitively impaired, should be given the hepatitis B vaccine series upon employment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link&amp;anchor=H3#H3\">",
"     \"Hepatitis B virus vaccination\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, although the risk for transmitting HIV through saliva is extremely low, infection is of concern if there is blood in the saliva. Counseling regarding post-exposure HIV prophylaxis is appropriate in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Infected bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;To successfully manage an infected wound, the clinician must recognize early signs of infection and be aware of the likely pathogens. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Infected wound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If a bite wound appears to be infected, the following actions should be taken:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove suture material, if previously repaired.",
"     </li>",
"     <li>",
"      Obtain Gram stain and aerobic and anaerobic cultures from the depth of an infected puncture or laceration prior to the initiation of antibiotics. The laboratory requisition should note that an animal or human bite wound is the culture source.",
"     </li>",
"     <li>",
"      Draw aerobic and anaerobic blood cultures prior to antibiotic therapy in patients with signs of systemic infection.",
"     </li>",
"     <li>",
"      Consult a surgeon for possible operative exploration, debridement, and drainage if abscess formation or suspected infection of bone, joint, or other major underlying structure (eg, clenched fist infections and other hand infections) is present. Debrided material should be sent for aerobic and anaerobic culture.",
"     </li>",
"     <li>",
"      Hospitalize patients with systemic symptoms or progression or development of infection despite receiving oral antibiotics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a bite becomes infected, it is crucial to perform aggressive debridement and abscess drainage, as indicated, and to administer intravenous broad-spectrum antibiotics to cover probable infecting bacteria in patients with dog or cat bites (",
"    <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"     table 1",
"    </a>",
"    ) or human bites (",
"    <a class=\"graphic graphic_table graphicRef80019 \" href=\"UTD.htm?43/40/44684\">",
"     table 2",
"    </a>",
"    ). A common approach involves initial IV therapy until infection is resolving followed by oral therapy to complete a course of 10 to 14 days.",
"   </p>",
"   <p>",
"    Superficial wound infections without abscess formation may be managed with wound debridement, oral antibiotic therapy, and close outpatient follow-up.",
"   </p>",
"   <p>",
"    Deeper structure infection (eg, osteomyelitis) requires a longer duration of therapy. Consultation with an infectious disease specialist is warranted for complicated infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H5#H5\">",
"     \"Soft tissue infections due to dog and cat bites\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Unusual animal bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of wound management remain the same for bites by other animals. The bites of most small animals, such as squirrels, rodents (eg, rats), rabbits, and guinea pigs, should generally be treated in the same fashion as cat bites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/35\">",
"     35",
"    </a>",
"    ].The potential for deep structure injury and life-threatening wounds increases with the size of the animal involved (eg, alligators, sharks, large carnivores) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis and empiric antibiotic therapy for infected wounds typically involves broad spectrum coverage of Gram positive, Gram negative, and anaerobic bacteria, similar to victims of dog or cat bites. In some instances, pathogens in bite wounds are significantly different (eg, Aeromonas species in alligator bites, Salmonella species in iguana bites, Vibrio species in shark bites) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. When possible, wound cultures should guide antimicrobial therapy for infected wild animal bites. Depending on the species, bacterial, fungal, or viral cultures may be necessary. Consultation with an infectious disease specialist is recommended for bites by exotic animals.",
"   </p>",
"   <p>",
"    Over time, the spectrum of animals that are kept as pets has grown. As a result, the types of zoonoses from pet handling and secondary infection of superficial bites and scratches has increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=see_link\">",
"     \"Zoonoses from pets other than dogs and cats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=see_link\">",
"     \"Rat bite fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are discharged after initial care should follow-up with their primary care provider or other appropriate clinician within 24 to 48 hours to assess wound status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complications of animal bites include trauma to deep structures, and infections, either transmitted or arising in the wound. In addition children who have suffered dog bites requiring at least minor surgical intervention may develop symptoms of post-traumatic stress disorder (PTSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic infections &ndash; Any infected bite wound can progress to infection of underlying structures (eg, bone, joint, tendon) and to bloodstream infection.",
"      <br/>",
"      <br/>",
"      Human bites can transmit numerous other infections, including hepatitis viruses B (HBV) and C (HCV), primary syphilis (rare), and herpes simplex virus [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/33,41\">",
"       33,41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The risk for transmitting HIV through saliva is extremely low but is of concern if there is blood in the saliva. Counseling regarding post-exposure HIV prophylaxis is appropriate in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"       \"Management of healthcare personnel exposed to HIV\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Any patient negative for anti-HBs antibodies who is bitten by an individual positive for HBsAg should receive both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"       hepatitis B immune globulin",
"      </a>",
"      (HBIG) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef59736 \" href=\"UTD.htm?20/39/21116\">",
"       table 7",
"      </a>",
"      ). Individuals who work in facilities where the risk for human bites is high, such as institutions for the cognitively impaired, should be given the hepatitis B vaccine series upon employment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link&amp;anchor=H3#H3\">",
"       \"Hepatitis B virus vaccination\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Post-traumatic stress disorder &ndash; Children who have suffered dog bites requiring at least minor wound repair, particularly if the wounds are deep or multiple, may develop symptoms of post-traumatic stress disorder (PTSD) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/57/20377/abstract/40\">",
"       40",
"      </a>",
"      ]. In one prospective study, the parents of 22 children who presented to an emergency department for minor surgical treatment of dog bites agreed to complete a questionnaire and undergo a telephone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      personal interview about the circumstances of the injury and the child's behavior before and after it occurred. The interviews took place between two and nine months after the incident. Among the 22 children, 12 had symptoms of PTSD for at least one month (five children met all of the DSM-IV criteria and seven met only some) (",
"      <a class=\"graphic graphic_table graphicRef57500 \" href=\"UTD.htm?8/55/9085\">",
"       table 8",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      This study was limited by its size and methodology (validated questionnaires for PTSD were not used). Nonetheless, children who have been victims of dog bites severe enough to require minor surgical intervention should be considered to be at risk for PTSD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28161?source=see_link\">",
"       \"Patient information: Animal bites (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=see_link\">",
"       \"Patient information: Taking care of cuts and scrapes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       \"Patient information: Animal bites (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most animal bites are caused by dogs, cats, and humans. The predominant organisms in animal bite wounds are the oral flora of the biting animal as well as human skin flora (such as Staphylococci and Streptococci). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"       \"Soft tissue infections due to dog and cat bites\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"       \"Soft tissue infections due to human bites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The typical location and nature of the injury differs depending upon the animal inflicting the bite. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Wound assessment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After appropriate local anesthesia, the wound should be carefully explored to identify injury to underlying structures and the presence of a foreign body. Appropriate imaging should be obtained for deep bite wounds near bone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      joints and when a foreign body is suspected (eg, plain radiograph or ultrasound). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Plain radiographs and ultrasound'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Head computed tomography is warranted in patients with a deep dog bite to the scalp, including puncture wounds, especially in children less than two years of age. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Head computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a bite wound appears to be infected, Gram stain and aerobic and anaerobic cultures should be obtained prior to the initiation of antibiotics. Wound cultures are NOT indicated in clinically uninfected bite wounds as results do not correlate with the likelihood of infection or the pathogen that is present in patients with subsequent infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Infected wound'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Wound culture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wound irrigation and debridement of devitalized tissue are essential components in the initial management of bite wounds. The wound should be carefully explored to identify injury to underlying structures and the presence of a foreign body. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Wound preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"       \"Minor wound preparation and irrigation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest primary closure of open lacerations in healthy patients that meet all of the following criteria (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cosmetically important (eg, facial lacerations)",
"     </li>",
"     <li>",
"      Wounds that are clinically uninfected",
"     </li>",
"     <li>",
"      Wounds less than 12 hours old (24 hours on the face)",
"     </li>",
"     <li>",
"      Wounds NOT located on the hand or foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sealing the wound with cyanoacrylate tissue adhesive (\"glue\") should be avoided. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Primary closure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Wound preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT closing wounds at high risk for the development of infection including the following types of wounds (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Crush injuries",
"     </li>",
"     <li>",
"      Puncture wounds",
"     </li>",
"     <li>",
"      Bites involving the hands or feet",
"     </li>",
"     <li>",
"      Wounds more than 12 hours old (24 hours old on face)",
"     </li>",
"     <li>",
"      Cat or human bites (except those to the face)",
"     </li>",
"     <li>",
"      Bite wounds in compromised hosts (eg, immunocompromised, absent spleen or splenic dysfunction, venous stasis, diabetes mellitus [adults]) (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Primary closure'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetanus and rabies prophylaxis should be provided as indicated. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Tetanus and rabies prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical consultation may be indicated in selected circumstances. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Surgical consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are discharged after initial care should follow-up with their primary care provider or other appropriate clinician within 48 to 72 hours to assess wound status. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylaxis with oral antibiotics should be given for patient circumstances as outlined above (",
"      <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H8#H8\">",
"       \"Soft tissue infections due to dog and cat bites\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H6#H6\">",
"       \"Soft tissue infections due to human bites\", section on 'Antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with deep or severe wound infections are treated with intravenous rather than oral antibiotics (",
"      <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80019 \" href=\"UTD.htm?43/40/44684\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Infected bites'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H8#H8\">",
"       \"Soft tissue infections due to dog and cat bites\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H6#H6\">",
"       \"Soft tissue infections due to human bites\", section on 'Antibiotics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Virus transmission after human bite",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient negative for anti-HBs antibodies who is bitten by an individual positive for HBsAg should receive both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"       hepatitis B immune globulin",
"      </a>",
"      (HBIG) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef59736 \" href=\"UTD.htm?20/39/21116\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Viral prophylaxis after human bites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for transmitting HIV through saliva is extremely low but is of concern if there is blood in the saliva. Counseling regarding post-exposure HIV prophylaxis is appropriate in this setting. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Viral prophylaxis after human bites'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"       \"Management of healthcare personnel exposed to HIV\"",
"      </a>",
"      .)&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Byrington CL, Basow RD. Streptobacillus moniliformis (rat-bite fever). In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL.  (Eds), Saunders, Philadelphia 2009. p.1788.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/2\">",
"      Goldstein EJ. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. J Med Microbiol 1998; 47:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/3\">",
"      Brook I. Human and animal bite infections. J Fam Pract 1989; 28:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/4\">",
"      Wiley JF 2nd. Mammalian bites. Review of evaluation and management. Clin Pediatr (Phila) 1990; 29:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/5\">",
"      Goldstein EJ. Management of human and animal bite wounds. J Am Acad Dermatol 1989; 21:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/6\">",
"      Oehler RL, Velez AP, Mizrachi M, et al. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis 2009; 9:439.",
"     </a>",
"    </li>",
"    <li>",
"     Hodge D, Tecklenburg FW. Bites and stings. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Williams &amp; Wilkins, Philadelphia 2006. p.1045.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/8\">",
"      Fleisher GR. The management of bite wounds. N Engl J Med 1999; 340:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/9\">",
"      Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/10\">",
"      Schalamon J, Ainoedhofer H, Singer G, et al. Analysis of dog bites in children who are younger than 17 years. Pediatrics 2006; 117:e374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/11\">",
"      Patronek GJ, Slavinski SA. Animal bites. J Am Vet Med Assoc 2009; 234:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/12\">",
"      Patrick GR, O'Rourke KM. Dog and cat bites: epidemiologic analyses suggest different prevention strategies. Public Health Rep 1998; 113:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/13\">",
"      Daniels DM, Ritzi RB, O'Neil J, Scherer LR. Analysis of nonfatal dog bites in children. J Trauma 2009; 66:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/14\">",
"      Goldstein EJ. Bite wounds and infection. Clin Infect Dis 1992; 14:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/15\">",
"      De Munnynck K, Van de Voorde W. Forensic approach of fatal dog attacks: a case report and literature review. Int J Legal Med 2002; 116:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/16\">",
"      Brogan TV, Bratton SL, Dowd MD, Hegenbarth MA. Severe dog bites in children. Pediatrics 1995; 96:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/17\">",
"      Chodakewitz J, Bia FJ. Septic arthritis and osteomyelitis from a cat bite. Yale J Biol Med 1988; 61:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/18\">",
"      Schweich P, Fleisher G. Human bites in children. Pediatr Emerg Care 1985; 1:51.",
"     </a>",
"    </li>",
"    <li>",
"     Prescott PR. Child abuse and neglect. In: A Practical Guide to Pediatric Intensive Care, Levin DL.  (Ed), Mosby, St. Louis 1984. p.454.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/20\">",
"      Moran GJ, Talan DA. Hand infections. Emerg Med Clin North Am 1993; 11:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/21\">",
"      Phair IC, Quinton DN. Clenched fist human bite injuries. J Hand Surg Br 1989; 14:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/22\">",
"      Boenning DA, Fleisher GR, Campos JM. Dog bites in children: epidemiology, microbiology, and penicillin prophylactic therapy. Am J Emerg Med 1983; 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/23\">",
"      Callaham M. Prophylactic antibiotics in common dog bite wounds: a controlled study. Ann Emerg Med 1980; 9:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/24\">",
"      Sutton LN, Alpert G. Brain abscess following cranial dog bite. Clin Pediatr (Phila) 1984; 23:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/25\">",
"      Klein DM, Cohen ME. Pasteurella multocida brain abscess following perforating cranial dog bite. J Pediatr 1978; 92:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/26\">",
"      Iannelli A, Lupi G. Penetrating brain injuries from a dog bite in an infant. Pediatr Neurosurg 2005; 41:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/27\">",
"      Chisholm CD, Schlesser JF. Plantar puncture wounds: controversies and treatment recommendations. Ann Emerg Med 1989; 18:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/28\">",
"      Halaas GW. Management of foreign bodies in the skin. Am Fam Physician 2007; 76:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/29\">",
"      Faciszewski T, Coleman DA. Human bite wounds. Hand Clin 1989; 5:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/30\">",
"      Kannikeswaran N, Kamat D. Mammalian bites. Clin Pediatr (Phila) 2009; 48:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/31\">",
"      Maimaris C, Quinton DN. Dog-bite lacerations: a controlled trial of primary wound closure. Arch Emerg Med 1988; 5:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/32\">",
"      Chen E, Hornig S, Shepherd SM, Hollander JE. Primary closure of mammalian bites. Acad Emerg Med 2000; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/33\">",
"      Muguti GI, Dixon MS. Tetanus following human bite. Br J Plast Surg 1992; 45:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/34\">",
"      Havens PL, American Academy of Pediatrics Committee on Pediatric AIDS. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003; 111:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/35\">",
"      Snyder CC. Animal bite wounds. Hand Clin 1989; 5:571.",
"     </a>",
"    </li>",
"    <li>",
"     Freer L. Bites and injuries inflicted by wild and domestic animals. In: Wildnerness Medicine, 5th, Auerbach PS.  (Ed), Mosby Elsevier, Philadelphia 2007. p.1133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/37\">",
"      Flandry F, Lisecki EJ, Domingue GJ, et al. Initial antibiotic therapy for alligator bites: characterization of the oral flora of Alligator mississippiensis. South Med J 1989; 82:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/38\">",
"      Kelsey J, Ehrlich M, Henderson SO. Exotic reptile bites. Am J Emerg Med 1997; 15:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/39\">",
"      Pavia AT, Bryan JA, Maher KL, et al. Vibrio carchariae infection after a shark bite. Ann Intern Med 1989; 111:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/40\">",
"      Peters V, Sottiaux M, Appelboom J, Kahn A. Posttraumatic stress disorder after dog bites in children. J Pediatr 2004; 144:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/57/20377/abstract/41\">",
"      Richman KM, Rickman LS. The potential for transmission of human immunodeficiency virus through human bites. J Acquir Immune Defic Syndr 1993; 6:402.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6593 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20377=[""].join("\n");
var outline_f19_57_20377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dog bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cat bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Human bites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pediatric wounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clenched fist injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infected wound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Wound culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Plain radiographs and ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Head computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Wound preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Puncture wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Primary closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Risk of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Delayed primary closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Surgical consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Tetanus and rabies prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Viral prophylaxis after human bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Infected bites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Unusual animal bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Wound assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Virus transmission after human bite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6593|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/2/1057\" title=\"picture 1\">",
"      Dog bite uninfected",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/4/27712\" title=\"picture 2\">",
"      Intentional human bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/3/34879\" title=\"picture 3\">",
"      Infected dog bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/10/1185\" title=\"picture 4\">",
"      Dog bite with fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/45/27356\" title=\"table 1\">",
"      Empiric intravenous antibiotic therapy for animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/40/44684\" title=\"table 2\">",
"      Empiric intravenous antibiotic therapy for human bite wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/4/37964\" title=\"table 3\">",
"      Empiric oral antibiotics animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/17/6429\" title=\"table 4\">",
"      Oral antibiotics human bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 5\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/43/28347\" title=\"table 6\">",
"      Rabies postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/39/21116\" title=\"table 7\">",
"      Postexposure prophylaxis hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/55/9085\" title=\"table 8\">",
"      Diagnosis posttraumatic stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=related_link\">",
"      Pasteurella infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28161?source=related_link\">",
"      Patient information: Animal bites (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=related_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=related_link\">",
"      Rat bite fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=related_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20378="Lopinavir and ritonavir: Drug information";
var content_f19_57_20378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lopinavir and ritonavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30933?source=see_link\">",
"    see \"Lopinavir and ritonavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/16/27914?source=see_link\">",
"    see \"Lopinavir and ritonavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV infection (as a component of combination therapy):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Twice-daily dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Therapy-naive or therapy-experienced: Lopinavir 400 mg/ritonavir 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     This regimen is preferred (with zidovudine and lamivudine or zidovudine and emtricitabine) in pregnant therapy-naive patients (DHHS, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Therapy-naive or therapy-experienced patients receiving efavirenz, fosamprenavir, nelfinavir, nevirapine: Lopinavir 500 mg/ritonavir 125 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     lopinavir 533 mg/ritonavir 133 mg solution twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     Therapy-naive or experienced patients with &lt;3 lopinavir resistance-associated substitutions: Lopinavir 800 mg/ritonavir 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for combination therapy with efavirenz, fosamprenavir, nelfinavir, or nevirapine:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Twice-daily dosing:",
"     </i>",
"     Therapy-naive and therapy-experienced patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution: Lopinavir 533 mg/ritonavir 133 mg (6.5 mL) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: Lopinavir 500 mg/ritonavir 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     Not recommended in those receiving efavirenz, fosamprenavir, nevirapine, nelfinavir, carbamazepine, phenobarbital, phenytoin.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/16/27914?source=see_link\">",
"      see \"Lopinavir and ritonavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV infection (component of combination therapy):",
"     </b>",
"     Oral: Dosage based on weight or body surface area (BSA),",
"     <b>",
"      presented based on lopinavir component",
"     </b>",
"     (maximum dose: Lopinavir 400 mg/ritonavir 100 mg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 days to 6 months: 16 mg/kg or 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Should not be administered to neonates age &lt;14 days (defined as postmenstrual age of 42 weeks [first day of mother&rsquo;s last menstrual period to birth plus postnatal age]) and a postnatal age of at least 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 months to 18 years:",
"     <b>",
"      Note:",
"     </b>",
"     FDA-approved dose is approximately equivalent to lopinavir 230 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     per dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;15 kg: 12 mg/kg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-40 kg: 10 mg/kg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: Lopinavir 400 mg/ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for combination therapy with efavirenz, fosamprenavir, nelfinavir, or nevirapine:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Twice-daily dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 14 days to 6 months: Combination therapy with these agents is not recommended due to lack of data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6 months to 18 years: Solution or tablet (",
"     <b>",
"      based on mg of lopinavir component",
"     </b>",
"     ): FDA-approved dose is approximately equivalent to lopinavir 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     per dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;15 kg: 13 mg/kg twice daily (",
"     <b>",
"      Note:",
"     </b>",
"     Tablets are not recommended)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15-45 kg: 11 mg/kg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;45 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     Not recommended in children.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial studies did not include enough elderly patients to determine effects based on age. Use with caution due to possible decreased hepatic, renal, and cardiac function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F189782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Has not been studied in patients with renal impairment; however, a decrease in clearance is not expected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Do not use once-daily dosing in hemodialysis patients (DHHS, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F189783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Use caution in hepatic impairment (metabolized primarily by the liver).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: Lopinavir AUC may be increased ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: No data available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaletra&reg;: Lopinavir 80 mg and ritonavir 20 mg per 1 mL (160 mL) [contains ethanol 42.4%, menthol, propylene glycol; cotton candy flavor]]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaletra&reg;:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Lopinavir 100 mg and ritonavir 25 mg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Lopinavir 200 mg and ritonavir 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7885304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143461.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143461.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F189757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Administer with food; if using didanosine, take didanosine 1 hour before or 2 hours after lopinavir/ritonavir. Administer using calibrated dosing syringe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: May be taken with or without food. Swallow whole, do not break, crush, or chew. May be taken with didanosine when taken without food. Tablets are not recommended in patients &lt;15 kg.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potential for dispensing errors between Kaletra&reg; and Keppra&reg; (levETIRAcetam)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Children&rsquo;s doses are based on weight and calculated by milligrams of lopinavir. Care should be taken to accurately calculate the dose. The oral solution contains lopinavir 80 mg and ritonavir 20 mg per one mL. Children &lt;12 years of age (and &le;40 kg) who are not taking certain concomitant antiretroviral medications will receive &lt;5 mL of solution per dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data presented for short- and long-term combination antiretroviral therapy in both protease inhibitor experienced and na&iuml;ve patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (children 12%; adults &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (3% to 39%), triglycerides increased (3% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7% to 28%; greater with once-daily dosing), abnormal taste/taste perversion (children 22%; adults &lt;2%), vomiting (children 21%; adults 2% to 6%), nausea (5% to 16%), abdominal pain (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: GGT increased (10% to 29%), ALT increased (grade 3/4: 1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 6%), insomnia (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (&le;5%), hyperuricemia (&le;5%), sodium decreased or increased (children 3%),",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Amylase increased (3% to 8%), dyspepsia (&le;6%), lipase increased (3% to 5%), flatulence (1% to 4%), weight loss (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Platelets decreased (grade 3/4: 4% children), neutropenia (grade 3/4: 1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (grade 3/4: 2% to 10%), bilirubin increased (children 3%; adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;2% (Limited to important or life-threatening): Abdominal distension, abnormal dreams, abnormal ejaculation, abnormal thinking, abnormal vision, acne, agitation, allergic reaction, alopecia, amnesia, anemia, anorexia, anxiety, apathy, appetite increased/decreased, arthralgia, asthma, ataxia, atrial fibrillation, atrioventricular block, AV block (second and third degree), avitaminosis, back pain, bacterial infection, benign neoplasm, body fat redistribution, bone necrosis, bradyarrhythmia, breast enlargement, bronchitis, cellulitis, cerebral infarction, chest pain, chills, cholangitis, cholecystitis, confusion, constipation, cough, creatinine clearance decreased, Cushing's syndrome, cyst, deep vein thrombosis, dehydration, depression, diabetes mellitus, dizziness, dry skin, dyskinesia, dysphagia, dyspnea, eczema, edema, emotional lability, encephalopathy, enteritis, enterocolitis, eructation, erythema multiforme, esophagitis, exfoliative dermatitis, extrapyramidal symptoms, facial edema, facial paralysis, fatigue, fatty deposits, fecal incontinence, fever, flu-like syndrome, folliculitis, furunculosis, gastritis, gastroenteritis, GERD, glucose intolerance, gynecomastia, hemorrhagic colitis, hemorrhoids, hepatic dysfunction, hepatitis, hepatomegaly, hyperacusis, hyperhidrosis, hypertension, hypertonia, hypertrophy, hypogonadism (males), hypothyroidism, immune reconstitution syndrome, impotence,  inorganic phosphorus decreased, jaundice, lactic acidosis, leukopenia, libido decreased, liver tenderness, lung edema, lymphadenopathy, maculopapular rash, malaise, MI, migraine, mouth ulceration, myalgia, neoplasm, nephritis, nervousness, neuropathy, obesity, orthostatic hypotension, otitis media, palpitation, pancreatitis, paresthesia, periodontitis, peripheral edema, peripheral neuropathy, pharyngitis, propylene glycol toxicity (preterm neonates [includes cardiomyopathy, lactic acidosis, acute renal failure, respiratory complications]), PR prolongation, pruritus, QT prolongation, rhinitis, seborrhea, seizure, sialadenitis, sinusitis, skin discoloration, skin ulcer, somnolence, splenomegaly, Stevens-Johnson syndrome, stomatitis, striae, thrombophlebitis, tinnitus, torsade de pointes, tremor, vasculitis, vertigo, viral infection, weight gain, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis) to lopinavir, ritonavir, or any component of the formulation; coadministration with medications highly dependent upon CYP3A4 for clearance for which increased levels are associated with serious and/or life-threatening events; coadministration with alfuzosin, cisapride, ergot alkaloids (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), lovastatin, midazolam (oral), pimozide, rifampin, sildenafil (when used for pulmonary arterial hypertension [Revatio&reg;]), simvastatin, St John's wort, triazolam",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Once-daily dosing: Patients with &ge;3 lopinavir-resistance-associated substitutions (L10F/I/R/V, K20M/N/R, L24I, L33F, M36I,  I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V); those receiving amprenavir, efavirenz, nevirapine, or nelfinavir, carbamazepine, phenobarbital, phenytoin, or in children &lt;18 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction and prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     and/or PR interval; second and third degree AV block and torsade de pointes have been observed. Use with caution in patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease or cardiomyopathies. Avoid use in combination with QT",
"     <sub>",
"      c",
"     </sub>",
"     - or PR-interval prolonging drugs or in patients with hypokalemia or congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased cholesterol: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: May cause hepatitis and/or exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying hepatic disease, such as hepatitis B or C, cirrhosis, or unspecified hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Use with caution in patients with increased triglycerides; pancreatitis has been observed. Patients with history of pancreatitis may be at increased risk. Monitor serum lipase and amylase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of lopinavir and ritonavir with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety, efficacy, and pharmacokinetic profiles of lopinavir and ritonavir have not been established for neonates &lt;14 days of age. Neonates &lt;14 days of age, particularly preterm neonates, are at risk for developing propylene glycol toxicity with use of the lopinavir/ritonavir oral solution. Oral solution contains ethanol and propylene glycol; ethanol competitively inhibits propylene glycol metabolism. Postmarketing reports in preterm neonates following use of the oral solution include cardiotoxicity (complete AV block, bradycardia, cardiomyopathy), lactic acidosis, CNS depression, respiratory complications, acute renal failure, and death. The oral solution should not be used in the immediate postnatal period, including full-term neonates age &lt;14 days or preterm neonates until 14 days after their due date, unless the infant is closely monitored and benefits clearly outweigh risk. Once-daily dosing (oral solution or tablets) is not an approved regimen for children &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral solution: The oral solution is highly concentrated and contains large amounts of ethanol (42.4%) and propylene glycol (15.3%). Healthcare providers should pay special attention to accurate calculation, measurement, and administration of dose. Overdose (or cumulative ethanol or propylene glycol content in medications) in a child may lead to lethal ethanol or propylene glycol toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Once-daily dosing is not recommended in patients with &ge;3 of the following lopinavir-resistance-associated amino acid substitutions in protease (L10F/I/R/V, K20M/N/R, L24I, L33F, M36I,  I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V); those receiving amprenavir, efavirenz, fosamprenavir, nevirapine, or nelfinavir, carbamazepine, phenobarbital, phenytoin, or in children &lt;18 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F189791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Ritonavir may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Ritonavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking lopinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting lopinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Lopinavir may decrease the serum concentration of BuPROPion. Concentrations of the active metabolite, hydroxybupropion, may also be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Ritonavir may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Lopinavir. Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with carbamazepine. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Ritonavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Lopinavir may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Ritonavir may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Ritonavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Lopinavir may decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution, which must be taken with food, and is principally the result of a food-didanosine interaction.  Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of lopinavir/ritonavir oral solution (which must be taken with food).  Didanosine and lopinavir/ritonavir tablets can be administered together.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Ritonavir. This is specific for the lopinavir/ritonavir (Kaletra) oral solution due to its alcohol content (42%). Management: Concomitant use of Kaletra (lopinavir/ritonavir) oral solution and disulfiram should be avoided. Kaletra contains 42% alcohol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronabinol: Ritonavir may increase the serum concentration of Dronabinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Lopinavir. Management: Avoid once daily use of lopinavir/ritonavir with efavirenz.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for specific recommended dose increases in particular patient populations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estazolam: Ritonavir may increase the serum concentration of Estazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Ritonavir may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Ritonavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Ritonavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): Ritonavir may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Lopinavir. Specifically, amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir. Management: Lopinavir/ritonavir should not be used as a once daily regimen when used together with fosamprenavir.  The use of ritonavir-boosted fosamprenavir with lopinavir/ritonavir may negate this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin. Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Lopinavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Ritonavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Ritonavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Ritonavir may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: Ritonavir may increase the serum concentration of Linagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Ritonavir. A disulfiram-like reaction could occur due to the alcohol contained in Kaletra (lopinavir/ritonavir) oral solution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Lopinavir may increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. Nelfinavir may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with nelfinavir.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Lopinavir. Management: Avoid once daily use of lopinavir/ritonavir with nevirapine.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Lopinavir. Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with phenobarbital. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Lopinavir may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir.  Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.  Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ritonavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Ritonavir may increase the serum concentration of PrednisoLONE (Systemic).  Management: Consider prednisolone dose reductions in patients receiving ritonavir and monitor for increased adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Ritonavir may increase the serum concentration of PredniSONE.  Management: Consider prednisone dose reductions in patients receiving ritonavir, and monitor for increased prednisone levels/adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Ritonavir may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Ritonavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Lopinavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Lopinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Lopinavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Lopinavir may increase the serum concentration of Rilpivirine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Ritonavir may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving ritonavir may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Lopinavir may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Ritonavir may decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Lopinavir may enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Lopinavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamcinolone (Systemic): Ritonavir may enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Lopinavir may increase the serum concentration of VinBLAStine.  Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Ritonavir may increase the serum concentration of VinBLAStine.  Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Lopinavir may increase the serum concentration of VinCRIStine.  Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Ritonavir may increase the serum concentration of VinCRIStine.  Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Ritonavir may decrease the serum concentration of Voriconazole.  Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Lopinavir may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Lopinavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Ritonavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F189772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Moderate- to high-fat meals increase the C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC of lopinavir/ritonavir oral solution; no significant changes observed with oral tablets. Management: Take oral solution with food; take tablet with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels of protease inhibitors and lead to possible resistance. Garlic may decrease the serum concentration of protease inhibitors. Management: Concurrent use of St John's wort is contraindicated. Avoid garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not seen in animal reproduction studies, except at doses which were also maternally toxic. Lopinavir/ritonavir crosses the placenta; however, based on information collected by the Antiretroviral Pregnancy Registry, an increased risk of teratogenic effects has not been observed in humans. The DHHS Perinatal HIV Guidelines consider lopinavir/ritonavir to be the preferred protease inhibitor for use in antiretroviral-naive pregnant women. Due to a decrease in bioavailability, a dose increase is suggested during the second and third trimesters of pregnancy, especially in PI-experienced women. Monitor virologic response (and lopinavir serum concentrations if available) if the standard dose is used. Once-daily dosing is not recommended during pregnancy. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F189764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F189765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solution should be taken with food. Tablet may be taken with or without food",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Kaletra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-100 mg/5 mL (160 mL): $461.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Kaletra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-25 mg (60): $230.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-50 mg (120): $922.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F189752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triglycerides, cholesterol, LFTs, electrolytes, basic HIV monitoring, viral load and CD4 count, glucose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aluvia (CL, PE, TH);",
"     </li>",
"     <li>",
"      Kaletra (AE, AR, AT, AU, BB, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IQ, IR, IT, JM, JO, KP, KW, LB, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PK, PL, PR, PT, PY, QA, RU, SA, SE, SG, SK, SR, SV, SY, TH, TR, TT, TW, UY, VE, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A coformulation of lopinavir and ritonavir. The lopinavir component binds to the site of HIV-1 protease activity and inhibits the cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles. The ritonavir component inhibits the CYP3A metabolism of lopinavir, allowing increased plasma levels of lopinavir.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ritonavir:",
"     </b>",
"     See Ritonavir monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lopinavir:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 98% to 99%; decreased with mild-to-moderate hepatic dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; 13 metabolites identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak, plasma: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Feces (83%, 20% as unchanged drug); urine (10%; &lt;3% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9982 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20378=[""].join("\n");
var outline_f19_57_20378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189776\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189777\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189796\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189780\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189790\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189781\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189782\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189783\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189754\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189740\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885304\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189757\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189755\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189804\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189794\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189760\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189744\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189791\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189748\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189772\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189750\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189763\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189786\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189764\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189765\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189762\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189752\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189766\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189743\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189759\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30933?source=related_link\">",
"      Lopinavir and ritonavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/16/27914?source=related_link\">",
"      Lopinavir and ritonavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_57_20379="One way sensitivity analysis";
var content_f19_57_20379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity analysis on the life expectancy of Outcome 1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Value of V",
"        <sub>",
"         1",
"        </sub>",
"        (life expectancy of Outcome 1)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected value of Choice 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected value of Choice 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        Choice 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        Choice 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        11.1",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        Choice 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11.0",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        Choice 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12.0",
"       </td>",
"       <td>",
"        12.0",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        Choice 1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20379=[""].join("\n");
var outline_f19_57_20379=null;
var title_f19_57_20380="Recommendations for the difficult fluid resuscitation";
var content_f19_57_20380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for the difficult fluid resuscitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        At 12-18 h postburn, calculate the projected 24 h resuscitation if fluid rates are kept constant. If the projected 24 h resuscitation requirement exceeds 6 mL/kg/percent TBSA then the following steps are recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Initiate 5 percent albumin early as described previously in the Emergency War Surgery Handbook.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Check bladder pressures every 4 h.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. If Urine Output (UOP) &lt;30 mL/h, strongly consider the placement of a Pulmonary Artery (PA) catheter to guide resuscitation with specific Pulmonary Capillary Wedge Pressure (PCWP) and Mixed Venous Saturation (SvO2) goals. (Goal PCWP 10-12, SvO2 65 percent-70 percent). If PA catheter placement is not practical then consider monitoring Central Venous Pressures (CVP) from a subclavian or IJ along with Central Venous (ScvO2) saturations. (Goal CVP 8-10, ScvO2 60 percent-65 percent).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. If CVP or PCWP not at goal then increase fluid rate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. If CVP or PCWP at goal then consider vasopressin 0.04 units/min to augment MAP (and thus UOP) or Dobutamine 5 mcg/kg/min (titrate until SvO2 or ScvO2 at goal). Max dose of Dobutamine is 20 mcg/kg/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. If both CVP or PCWP and SvO2 or ScvO2 at goal then stop increasing fluids (EVEN if UOP &lt;30 mL/hr). The patient should be considered hemodynamically optimized and the oliguria is likely a result of established renal insult. Some degree of renal failure should be tolerated and expected. Continued increases in fluid administration despite optimal hemodynamic parameters will only result in \"resuscitation morbidity\", that is oftentimes more detrimental than renal failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. If the patient becomes hypotensive along with oliguria (UOP &lt;30 mL/hr), then follow the hypotension guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Every attempt should be made in minimize fluid administration while maintaining organ perfusion. If UOP &gt;50 mL/h, then decrease the fluid rate by 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After 24 h, LR infusion should be titrated down to maintenance levels and albumin continued until the 48 h mark.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ennis JL, Chung KK, Renz EM, et al. Joint theater trauma system implementation of burn resuscitation guidelines improves outcomes in severely burned military casaualties. J Trauma 2008; 65:S146. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20380=[""].join("\n");
var outline_f19_57_20380=null;
var title_f19_57_20381="Pravastatin improves CHD risk";
var content_f19_57_20381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pravastatin improves outcome in hypercholesterolemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 264px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Probability (in percent) of a cardiovascular event in patients with a plasma cholesterol concentration between 200 and 300 mg/dL (5.2 to 6.2 mmol/L) and two additional coronary risk factors who were treated with placebo or pravastatin. Pravastatin diminished the incidence of cardiovascular events, a benefit that was demonstrated within six months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Pravastatin Multinational Study Group for Cardiac Risk Patients, Am J Cardiol 1993; 72:1031.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20381=[""].join("\n");
var outline_f19_57_20381=null;
var title_f19_57_20382="Evaluation algorithm for chronic constipation";
var content_f19_57_20382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F88130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F88130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Evaluation algorithm for chronic constipation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 394px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MR: magnetic resonance.",
"     <br/>",
"     * Because anorectal manometry, rectal balloon expulsion test may not be available in all practice settings, it is acceptable in such circumstances to proceed to assessing colonic transit with the understanding that delayed colonic transit does not exclude a defecatory disorder.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. Gastroenterology 2013; 144:211. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20382=[""].join("\n");
var outline_f19_57_20382=null;
var title_f19_57_20383="American dog tick";
var content_f19_57_20383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An adult female dermacentor variabilis (American dog tick)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_57_20383=[""].join("\n");
var outline_f19_57_20383=null;
